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  The goal of this work is to develop novel method for organizing gold 
nanoparticles by linking them to chemically reactive side chains amino acids (e.g., lysine 
and cysteine) and then incorporating these modified amino acids into a polypeptide 
through in vitro translation of a synthetic mRNA template.  The use of this system not 
only provides a method for the supramolecular assembly of new bio-inorganic 
heterostructures, using ribosomes as natural molecular machines and an artificial coding 
template, but also provides a new tool for probing fundamental biological processes (e.g., 
translation).   
Transfer RNA (tRNA) is transcribed in vitro from a plasmid-template containing 
the tRNA gene under control of the T7 promoter.  A novel coupled transcription–
aminoacylation (CTA) system which prepares large amounts of pure aminoacyl-tRNA in 
a single reaction mixture was developed.  Radiolabeled [32P]-UTP and [14C] or [32S]-
amino acid are used to monitor the coupled transcription- aminoacylation reactions.  The 
ability to further modify the tRNA with a biotinylated probe is also demonstrated.   The 
 viii
tRNA synthesized by CTA, or further modified with biotin is shown to retain its 
functionality in in vitro translation, allowing the synthesis and detection of biotin-labeled 
protein.   
Following the charging of the tRNA, the side chain of the amino acid is 
covalently linked to a gold nanoparticle, i.e. Monomaleido or Mono-sulfo-N-
hydroxysuccinimide Nanogolds, either directly or through a heterobifunctional linker, 
which may vary in length and/or chemical properties, depending on the system used.  
The result is a novel gold nanoparticle-conjugated tRNA.  Each of the steps is verified 
by mass spectroscopy (ESI and/or MALDI).  The attachment of the gold nanoparticle to 
modified aminoacyl-tRNA is confirmed using High angle annular dark field images 
(HTEM) and laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS).  
The incorporation of the quantum dot-conjugated tRNA into a polypeptide is measured 
using an in vitro E. coli  S30 cell-free coupled transcription-translation system, and 
verified by electrophoresis, laser ablation inductively coupled plasma mass spectrometry 
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The process of synthesizing proteins known as translation is complicated and 
takes place in three steps: initiation, elongation and termination.  Many components are 
required for the decoding of genetic information into proteins: the ribosome, a molecular 
machine that makes the peptide bond, messenger RNA (mRNA) to provide the template, 
aminoacylated transfer RNA (aa-tRNA) to bring the amino acids to be assembled and 
many other proteins, including aminoacyl-tRNA synthetases and translation initiation, 
elongation and termination factors.  The ribosome is the “stage” where proteins are 
formed and is a structure where the nucleic acid and protein worlds intersect.  The 
“enzymatic activity” of the ribosome, formation of peptide bonds into protein, is actually 
carried out in the 28S ribosomal RNA, thus the ribosome is a ribozyme.   
 
1. 1. PROTEIN BIOSYNTHESIS 
   
The translation process takes place in three parts, initiation, elongation and 
termination.  In the initiation step, an initiation complex is formed between the mRNA, 
a ternary complex composed of initiator met-tRNAi, initiation factor 2 (IF2) and GTP and 
the small ribosomal subunit.  The joining of the large ribosomal subunit is concomitant 
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with the hydrolysis of the GTP in the ternary complex.  The mRNA has to be placed on 
the 30S subunit so that the start codon is correctly positioned.  The selection and 
positioning of the start site is facilitated by the Shine-Dalgarno nucleotide sequence 
which is complementary to the 3’ end of 16s RNA.[1] 
Other initiation factors, IF3 and IF1 also participate in the process.  IF3 binds the 
small subunit preventing the association of ribosomal subunits prematurely [2, 3] and also 
is involved in the codon-anticodon discrimination between mRNA and initiator RNA.[2]  
After the IF3 is released, the 50S subunit joins the 30S initiation complex to yield the 
formation of 70S initiation complex.  The function of IF1 is still not clear; there is some 
thought that IF1 binds to the A-site preventing binding of the initiator tRNA, but 
crystallographic data shows the initiator tRNA binds to the P-site in the presence or 
absence of IF1.[4]  
The elongation step is the step where the peptide bond is formed, where three 
elongation factors assist the elongation process: EF-Tu, EF-Ts and EF-G.  A ternary 
complex consisting of EF-Tu, GTP and aa-tRNA brings the amino acids to the ribosome.  
If the correct amino acid is brought to the ribosome, then the EF-Tu is released 
accompanied by hydrolysis of GTP to form the EF-Tu•GDP complex and is released 
from the ribosome.  The GDP must be removed by a “recycling” factor, EF-Ts, so that 
the EF-Tu may bind GTP and form a new complex with another aa-tRNA.    
The aa-tRNA is placed in such way in the ribosome that the aminoacyl residue is 
docked in the transferase center or PFT center and ready for peptide bond formation.[5] 
The PFT center of the ribosome catalyzes the formation of the peptide bond.   
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The last stage in the elongation step is translocation.  Translocation involves the 
movement of the mRNA through the ribosome and ejection of empty tRNA.  This 
process is mediated by a protein called EF-G which mimics the EF-Tu-tRNA complex.  
The EF-G•GTP binds the ribosome and upon hydrolysis to EF-G•GDP facilitates the 
tRNA-mRNA movement within the ribosome.[6, 7]  After the translocation stage is 
completed, the ribosome is ready to accommodate a new aa-tRNA.  The elongation 
process is continued till one of the three stop codons (UAA, UAG and UGA) is 
encountered triggering the last step in the translation process.    
The last step in translation is called termination and the polypeptide is released 
and the ribosome is dissociated into its 30S and 50S subunits.  This process is mediated 
by three release factors: RF1 which binds the UAA and UAG stop codons; RF2 that binds 
the UGA stop codon and RF3 which is thought to be involved in the final translocation 
and helps the dissociation of the ribosome into its subunits and the release of the 
deacylated tRNA.[8]  The RF1 and RF2 mimic the structure of the tRNA and bind to the 
stop codons on the mRNA.  The release factors transfer a water molecule to the 
polypeptide chain and cause the nascent polypeptide to be released from the ribosome.   
1.2. THE RIBOSOME, A PROTEIN FACTORY: 
 
The prokaryotic ribosome is an efficient molecular machine.  A functional 70S 
ribosome is composed of two subunits, a small subunit with a sedimentation coefficient 
of 30S and a large subunit with a sedimentation coefficient of 50S and a molecular mass 
of approximately 2.6 X106 Da.[9]  Escherichia coli ribosomes are composed of proteins 
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(21 proteins in the 30S subunit and 33 proteins in the 50S subunit) and RNA (16S rRNA 
in small subunit and 5S and 23S rRNA in large subunit).   
In order to better understand how the ribosome works, it is necessary to know a 
detailed structure.  The first high resolution crystals structures for ribosomes were 
reported in 2000 and several structures have been described.[9-11]  The detailed 
structure of ribosomes opened a new era for elucidating the mechanism of protein 
synthesis. 
The structure of the ribosomal subunits showed that the proteins are situated 
mostly at the surface, and the inner core is formed from RNA.[9]  The main function of 
the majority of the proteins is to stabilize the 3D structure of the ribosomal RNAs. 
The primary function of the ribosome is to “decode” the mRNA and form a 
protein.  To carryout this function ribosomes must use tRNAs to bring the amino acid 
into the ribosome that corresponds to the codon on the mRNA.  This “decoding or 
deciphering” requires base pairing of the codon on the mRNA with the anticodon on the 
tRNA in the ribosomes.   
Ribosomes have three types of tRNA binding sites, Aminoacyl-, Peptidyl-, and 
Exit- sites that can accommodate tRNAs.  The A-site binds tRNAs carrying amino acids 
(aminoacylated or aa-tRNA), the P-site binds tRNA that has the growing peptide chain 
attached and the E site is for the tRNA that has donated its amino acid and is ready to 
leave the ribosome.  The tRNAs bind the ribosome through their acceptor stem in the 
large subunit and with their anticodon stem (codon-anticodon interaction) in the small 
subunit.   The accuracy of this process is monitored by the correct pairing between the 
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mRNA codons and the tRNAs anticodons.  If the base-pairing is incorrect, the aa-tRNA 
leaves the ribosome without discharging its amino acid.    
The peptidyl-site or P-site is where the tRNA carrying the nascent polypeptide 
chain waits for the next amino acid to be added to the growing polypeptide chain.  
Peptide bond formation takes place in the large subunit between the incoming aa-tRNA in 
the A-site and peptidyl-tRNA in the P-site and is catalyzed by the peptidyl transferase 
(PFT) activity.[11]  The PFT activity is actually the 23S rRNA.[11]  The peptidyl-
tRNA transfers the peptide chain to the next aa-tRNA.  The mechanism of PFT is still 
not fully understood; however, the carboxyl group from peptidyl-tRNA is attacked by the 
amino group  (α-NH2) from the incoming aa-tRNA to yield the formation of a tetrahedral 
intermediate compound with the A2451 nucleotide of 23S rRNA and subsequent 
formation of the peptide bond.[11-13]  
The exit site or E-Site, discovered in the late 1980’s is the site where the 
deacylated tRNA is placed before leaving the ribosome.  Except the initiator tRNA 
which binds directly to the P site, all the other tRNAs move through all three sites 
starting with the A-site, then P-site, and finally the E-site.  The movement of tRNA from 
one site to the other is called translocation and is catalyzed by elongation factors. 
Near the PTF center is a tunnel approximately 100 Å long that is continuous 
through the large subunit.[11]  This tunnel is believed to be the exit tunnel of the nascent 
protein.  The tunnel has an average diameter of 15 Å but in some regions the diameter 
ranges from 10-20Å.  The walls of this tunnel are made from nucleotides of the 23S 
rRNA and non-globular proteins (L22 and L4).[11, 14-16]  From the crystal structures, 
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one can conclude that the tunnel is too small to permit proteins to fold and therefore it is 
possible that the proteins begin the folding process only after they exit the tunnel.  
However, several studies showed that some proteins may exit the ribosome through 
alternate pathways.[15, 17]  
The ribosome’s crystal structure brought new perspectives to the understanding 
of the mechanism of protein biosynthesis.  However, many questions regarding the 
process are still unknown or are not completely understood.[18]  
1.3. AMINOACYL-TRNA –THE CODE “DECIPHER”  
 
One of the most important players in protein synthesis is the aminoacyl tRNA.  
To understand the process of translation it is necessary to comprehend the importance of 
the aminoacylation process.  The aminoacylation process takes place between a tRNA, 
its cognate amino acids and is catalyzed by a specific aminoacyl-tRNA synthetase to 
yield the aminoacyl-tRNA (aa-tRNA).  The accuracy of this reaction is vital to prevent 
incorrect amino acids from being placed into the growing polypeptide chain. 
The aa-tRNAs are synthesized in a two step process by the cognate aminoacyl-
tRNA synthetase.  In the first step of aminoacylation, an intermediary aminoacyl 
adenylate is formed between the amino acid and ATP and then subsequently the activated 
amino acid is transferred to the 3’ end of the tRNA.   
This process of aminoacylation is catalyzed by a family of enzymes, the 
aminoacyl-tRNA synthetase (aaRS).  There are ~20 such enzymes, one for each cognate 
amino acid and are classified into two groups based on their structural features.  The 
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differences between these two classes lies in their catalytic domains; Class I enzymes 
possess a Rossmann dinucleotide-binding domain as well as HIGH and KMSKS motifs, 
while Class II enzymes have six anti-parallel β-sheets and three α-helices which are 
referred to as the αβ active site.  Another salient difference between aaRS classes is the 
way the tRNAs “bind” to the enzymes.  Class I aaRS bind to the acceptor stem of tRNA 
from the minor groove side and acylation take place at 2’ hydroxyl group of the 3’ 
adenosine.  Meanwhile class II aaRS bind from the major groove side of the stem and 
acylation takes place at 3’ hydroxyl group of the 3’adenosine.[19-21] 
An example of a tRNA/aminoacyl-tRNA synthetase pair.  Escherichia coli 
cysteinyl-tRNA synthetase (CysRS) is the smallest monomeric synthetase and belongs in 
subclass Ia of tRNA synthetases.[20, 22]  The CysRS has 461 amino acid residues and 
the HIGH and KMSKS motifs are conserved.  These motifs are involved in the 
activation of cysteine and transfer of active cysteine to 3’ CCA end of the tRNA.[23, 24]  
All tRNAs have an L-shaped tertiary structure where the acceptor stem and the 
TψC stem form the short arm of the L-structure and the dihydrouridine (D) stem and 
anticodon stem forms the long arm of the L-structure.   The CysRS recognizes the 
tRNAcys tertiary structure based on indirect and direct interaction with the discriminatory 
base (U73-in the tRNAcys) [25-27], anticodon loop (GCA) [27, 28] and acceptor stem (3’ 
CCA).[21, 27]  The presence of the G15:G48, called the “Levitt pair”, in the tertiary 
structure of tRNAcys is an important factor in the recognition and aminoacylation of 
cysteine specific tRNA.  Studies have shown the need for G15:G48 for aminoacylation.  
If either base is mutated aminoacylation is abolished.[29, 30] 
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Studies have shown that a shape–selection mechanism between the tRNAcys and 
CysRS is important in aminoacylation.[28]  However, the tertiary structure of cysteine 
specific tRNA plays the decisive role in the formation of tRNAcys-CysRS complex, thus 
in cysteinylation. 
1.3.1. Unnatural Aminoacyl-tRNA a new area in modern biochemistry 
 
The aminoacyl-tRNA synthetases are a class of enzyme important in the fidelity 
of translation through the accurate matching the amino acid to their cognate tRNA.  
However, it is possible to alter amino acids with new functional groups.   Johnson and 
his coworkers derivatized for the first time a lysyl-tRNA with N-acetoxysuccimide.  
[31]  This was the beginning of a very interesting new technological area in 
biochemistry to use unnatural amino acids in the synthesis of proteins with new 
properties.  The strategy engaged by Johnson and his coworkers was to attach N-
acetoxysuccimide to the ε-amino group of lysyl-tRNAlys and then use this new Nε- acetyl-
lysyl-tRNAlys in a cell free rabbit reticulocyte system to translate hemoglobin.[31]  The 
limiting factors for this method are the incorporation of modified lysine residues in all the 
sites which encode lysine.  Mixed populations of proteins containing 
modified/unmodified lysine residues were present.  The presence of different cross 
linkers attached to the ε-amine group of lysyl-tRNA, was described previously in the 
literature.[31-38]  This technology is the basis for commercial kits using non-radioactive 
detection of chemiluminescent compounds attached to the modified lysyl-tRNA for easy 
visualization of the synthesized protein.[39-41]  Kadat and his coworkers reported the 
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attachment of a sulfhydryl spin-label compound (N-(l-oxyl-2, 2, 5, 5-tetramethyl-3-
Pyrrolidinyl) iodoacetamide) to cysteinyl-tRNA side chain.[42]  Lysine and cysteine are 
very attractive amino acids for derivitization due to their chemically reactive side chains. 
It would be more efficient to have the unnatural amino acid function as a 
substrate for the aaRS; however, aaRSs’ are very precise enzymes which acylate only a 
specific tRNA with their cognate amino acid, thus misacylation of tRNA with unnatural 
amino acids is very difficult to achieve.  To overcome this difficulty, it is necessary to 
chemically attach the amino acids to the tRNA [43-46], to “engineer” the synthetase to 
utilize a unnatural amino acid substrate [47, 48] or to create an “artificial” synthetase  
such as a ribozyme [49-54] to carryout the reaction.   
The chemical attachment of an amino acid was first reported by Hecht and his 
coworkers[43].  A T4 RNA ligase was employed to condense an E. coli phenylalanine 
specific tRNAPhe missing the last two nucleotides (C75 and A76) with several 2’ (3’)-O-
acylated pCpA derivatives.  The α-amino group of to the amino acid must be protected 
by a chemical group before the chemical aminoacylation but the protective group must be 
removed prior to translation.  Several years later, two independent groups took this 
method a step forward using the chemical acylation for site-specific incorporation of 
unnatural amino acids in proteins.  The site-specific incorporation is possible using a 
suppressor tRNA.  Suppressor tRNAs recognize the stop codons UAG (amber), UGA 
(opal), and UAA (ocher).  Instead of terminating translation, suppressor tRNAs insert an 
amino acid and allow translation to continue past the termination codon.  The use of 
suppressor tRNAs charged with unnatural amino acids would allow incorporation of the 
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unnatural amino acid at a specified site- using on the termination codons (amber, opal or 
ocher). 
Based on this methodology Schultz’s [46] and Chamberlin’s [44, 45] groups, 
independently, chemically misacylated an amber suppressor yeast phenylalanine specific 
tRNA CUA with a phenylalanine, para-fluorophenylalanine, para-nitrophenylalanine [46] 
and an E. coli  amber suppressor glycine specific tRNA CUA with a radiolabeled iodo-
tyrosine [44], respectively, and showed site-specific incorporation of the modified amino 
acid in proteins and short peptides.  Starting with these reports, in the last decade over 
100 different unnatural aminoacyl-tRNAs were reported.[55-60]  The applications for 
the site incorporation of the unnatural amino acids is vast and is closely related to the 
structure-function of a wide range of proteins in eukaryotic or prokaryotic systems.   
However, the chemical attachment and the in vitro site-specific incorporation of 
unnatural amino acids is limited by several important factors: (1) the suppressor tRNA 
has to be orthogonal (statistically independent) to the in vitro translation system; if the 
tRNA is not orthogonal the endogenous aminoacyl-tRNA synthetase present in the 
system, this will be acylated with its cognate natural amino acid and then incorporate into 
the protein as an unmodified amino acid residue, yielding the formation of a mixed 
population of proteins (modified/unmodified proteins); (2) the chemical attachment of 
unnatural amino acids is inefficient ; (3) the suppressor tRNA competes with the release 
factors present in the translation mixture and (4) apparently suppressor tRNAs charged 
with unnatural amino acids have very low suppression efficiency.[56, 57]  To overcome 
some of these problems yeast suppressor tRNA was used in in vitro E. coli translation 
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systems [46, 61] or E. coli  suppressor tRNA were used in eukaryotic translation 
systems.[44, 56]   The breakthrough came, when an orthogonal tRNA/aaRS pair was 
developed for use in in vivo translation.  The aaRS was evolved to recognize unnatural 
amino acids and aminoacylate the suppressor tRNA in vivo.[47]  This methodology has 
been further developed in Schultz’s group for a variety of non-natural amino acids.[55-
60] 
 Another promising solution for aminoacylation of tRNA with unnatural amino 
acids was developed by Suga and his coworkers.[49-54]  They showed that ribozymes 
can be used as an alternate method to aminoacylate a tRNA.  An acyl-transferase 
ribozyme which was evolved in vitro was demonstrated to specifically catalyze the 
aminoacylation reaction of an unnatural amino acid at the 3’ end of their cognate tRNA.  
The tRNAs are recognized by the ribozymes through the CCA-3’ end and also through 
the anticodon loop.  Ribozyme specificity towards different substrates is programmed 
into the internal guide sequence, which is the complementary sequence to the last five 
nucleotides at the 3’end of the tRNA.[49]  The possibility of using ribozymes as a 
catalyst for aminoacylation opens a new direction for the synthetic pathway of unnatural 
aminoacyl-tRNA. 
 Although a variety of amino acids modified with functional organic groups or 
single atoms (I or Hg) were described [62, 63], no modifications with nanoparticles or 
quantum dots (less or bigger than 10 nm) had been reported.  Modifying proteins with 
nanoparticles of various properties could have many potential applications. 
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1.4. QUANTUM DOTS  
 
 Quantum dots are zero-dimensional systems in which the charge carriers and the 
excitations are confined in all three directions of space, thus leading to discrete levels of 
energy, similar to the ones found in a single atom.  The energetic confinement of the 
electrons is translated in terms of the size of the atomic cluster by the fulfillment of 
certain conditions, i.e. the high symmetry (ideal case: spherical) and a particle size (<1-10 
nm) comparable with the de Broglie wavelength of its charge carriers.[64]  
Nanoparticles obeying these two shape and size requirements have an icosahedral 
geometry consisting of layered shells of highly packed atoms, in which the total number 
of atoms is given by the Mackay formula for sphere-packed icosahedral structures:  
n 
N = 1+ Σ  ( 10 p2 + 2) 
p=1 
 
where is p = the number of atom shells, N = total number of atoms 
Quantum dots of relevant importance, usually metals and inorganic 
semiconductors thus have fixed numbers of atomic constituents; usually 13 for one-shell 
quantum dots and 55 for two-shell nanoparticles and this corresponds to high percentages 
in terms of surface atoms: 92% and 76%, respectively.  The direct consequence of this 
unusually high ratio of surface atoms relative to the total number of constituent atoms is 
the high chemical reactivity of the quantum dots.  In order to protect the nanoparticles 
against agglomeration and self-aggregation, the quantum dots are capped with ligands 
that are most commonly organic molecules of various type and nature, depending on the 
practical applications considered.  The main feature of the quantum dots, the atom-like 
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discrete levels of energy is more significant for inorganic semiconductors, being more 
enhanced at the edges of the valence and conduction bands.  The discrete levels of 
energy in a quantum dot can be calculated by applying the particle-in-a-box model, in 
which the charge carriers are confined in all 3 directions and the potential energy, is zero 
anywhere inside the box and infinite at the walls of the box.  The allowed energy levels 
inside the box can be calculated applying the Schrumalaufedinger equation and if the 
shape of the box is spherical, the energy levels have the general form:  
    E   =   n2h2 / 2 m d2,  
where n is the energy level, m is the mass of the charge carrier and d is the diameter of 
the sphere .[64] 
 Quantum dots of semiconductor materials display an energy gap greater than in 
the bulk form and this particularity has a great impact upon their optical properties.[65] 
The minimum energy needed to form an electron-hole pair (exciton) is defined by the 
value of the valence band-conduction band gap and this increases as the dimension of the 
quantum dot decreases.[66]   Appropriate tailoring by specific chemical synthetic routes 
of the size of the semiconductor quantum dots results in particular, targeted values for the 
energy band gap and this important feature has important practical applications.  
Excitons in quantum dots poses a limited lifetime and their dissolution leads to 
fluorescence, which is defined as an emission of photons through a radioactive decay 
mechanism.[67]  The energy emitted through fluorescence of the quantum dots is 
always red-shifted (smaller) when compared to the minimum of energy (band gap) 
absorbed for the formation of the exciton in the first place.[68]  Metallic quantum dots 
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display optical absorption spectra similar to the semiconductor quantum dots but the 
nature of the energy transitions differ.  The metal nanoparticles possess collective modes 
of motion for the free electron gas (surface plasmons) and these can be excited by 
absorbing appropriate amounts of energy.  By contrast to their semiconductor 
counterparts, the metallic quantum dots do not have a significant dependence of the 
surface plasmons resonance frequency to the size of the nanoparticles. 
 Most of the important applications for the quantum dots involve the optical or 
electrical excitation which upon relaxation leads to generation of photons with a specific 
energy.  Thus, quantum dots may be used as single photon sources, lasing media, and 
charge storage media or as fluorescent labels.[69, 70]  
 
1.4.1. Nanotechnology tool for tagging biological substrates 
 
 During the last decade, developments from the newly emerging field of 
nanotechnology found biochemical applications and thus a new, promising area surfaced 
- nanobiotechnology.  This new field evolved rapidly from a conceptual tool to a 
research tool and has now reached the stage of a devise tool.[71]  The full potential of 
nanobiotechnology is still to be discovered but a few breakthroughs have already been 
reported in the scientific literature.[71-74]  The use of nanocrystals for biopolymer 
labeling opens a new direction in labeling and detection techniques for the biological 
substrates.  The need for radioactive isotopes or/and organic dyes may be minimized or 
potentially totally replaced by quantum dots.[73, 74]  Nanocrystals of various size and 
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composition have been used to conjugate to biological substrates, i.e. zinc sulfide-capped 
cadmium selenide (CdSe/ZnS) for detection of proteins [73-76] and oligonucleotides.[77-
80]  Besides the semiconductor quantum dots, i.e. zinc sulfide-capped cadmium selenide 
CdSe/ZnS, cadmium telluride (CdTe) [81] and titanium oxides (TiO2)[82], metal 
quantum dots, i.e. gold and silver nanoparticles, were used efficiently to visualize and 
detect biological substrates.[72, 83-85]  In addition, during the last year the 
nanobiotechnology evolved to the stage where the cell can by visualized and tracked [86, 
87] and DNA [88] and proteins [84] can be detected using bio-barcode oligonucleotides 
mo dified by a gold nanoparticle.  The synthetic pathways to generate these quantum 
dots or nanoparticles modified biopolymers are various and implicate several strategies: 
(i) electrostatic adsorption-nanoparticles have negative charge ions on the surface and 
interact with the positive charges of proteins [89, 90] ; (ii) chemisorptions of nanoparticle 
and /or quantum dots to proteins through the amino acids residues side chains i.e.  thiol 
group of cysteine [83] , or DNA modified with a cysteine residue [72, 91] ; (iii) covalent 
attachment of gold nanoparticles to DNA [72, 92, 93], RNA [94], and proteins [95]-the 
attachment it is possible through the single reactive group, i.e. sulfo-N-
hydroxysuccinimide ester or monomaleimido groups, present on the surface of the 
nanoparticle which is reactive towards different reactive groups, i.e.  ε-amino group 
belonging to lysine residues or sulfhydryl group from cysteine residues; (iv) through 
specific affinity interactions- nanoparticles conjugated with streptavidin interact with 
biotinylated proteins [96] or oligonucleotides [97] or interaction between  antibody  
conjugated nanoparticles with their cognate antigens [98].   In addition, Sweeny and 
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coworkers (2004) reported for the first time the possibility of using an E. coli  organism 
to synthesize cadmium sulfide nanocrystals (2-5 nm).[99]  
 Nanobiotechnology is a rapidly expanding field and many interesting 
discoveries are yet to come.  The interactions between these two very different and 
complex fields have already brought many changes to classic material science.   The 
complexity of biological substrates combined with the particular properties introduced by 
the quantum dot and/or nanoparticles will allow novel applications and has a virtually 
unlimited potential.   
1.5. IS IT POSSIBLE TO USE THE RIBOSOME TO MANUFACTURE AN INORGANIC 
MODIFIED AMINO ACID? 
 
The research described in this dissertation project was to determine if it was 
possible to use the ribosome to synthesize new bio-inorganic materials.   Specifically, 
modify amino acids with quantum dots and have the ribosome assemble polypeptides 
containing the quantum dots at specific sites in the polypeptide.  The major obstacles to 
be overcome were the stable attachment of the quantum dot to the amino acid and 
determining whether the ribosome would accept such a modified amino acid and use it 
for peptide bond formation. 
The quantum dots must be linked to the chemically reactive side chain of an 
amino acid, i.e. lysine (epsilon amino group) or cysteine (sulfhydryl group), that has 
already been assembled on the carrier tRNA by aminoacylation.  The integration of the 
quantum dot modified amino acid into polypeptide will be carried out by ribosomes in in 
vitro translation programmed with a messenger RNA (mRNA) template (see Figure 1.1).    
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If successful, this method will provide a method for the supramolecular assembly of new 
bioinorganic heterostructures, using ribosomes as natural molecular machines and an 
artificial coding template to regularly space the quantum dots.   
 




1.5.1. My ideal nanodot. 
 
 To use the ribosome to assemble quantum dot modified amino acids, a very 
special quantum dot would be required.   In the last few years several new types of 
nanodots have been synthesized that have a variety of different shapes [100], sizes (2-200 
nm, some under 1.2 nm) [101, 102] and have monodistribution.  One of the limitations 
of these quantum dots and/or nanoparticles is the multiple reaction sites present on the 
surface.  In the last two years, two groups reported the synthesis of gold nanoparticles 
with a single reactive group on the surface.[103-105]  These successful syntheses 
showed that the mono-functionalization of nanodots or nanoparticles is possible.   
Nanoprobes, Inc. makes 1.4 nm gold nanoparticles that have only one single reactive 
group on the surface.   Other types of nanoparticles that are derivatized with 
streptavidin or fluorescent groups are also available commercially from Nanoprobes.   
The nanoparticle/quantum dot needs to have the following characteristics.  The ideal 
quantum dot would be made from a semiconductor material which has fluorescent 
properties for ease of detection such as CdS, CdSe, ZnS, ZnSe, CdSecore/ZnSshell.   The 
quantum dot should also have a size under 2 nm, due to potential physical limitations of 
the ribosome exit tunnel (average diameter ~1.5nm).   The quantum dot should also 
have a single reactive group on the surface so it reacts with only one amino acid and be 
commercially available.  The only available particle that satisfies most of these 
requirements was the 1.5 nm Nanogold particles from Nanoprobes, Inc.  The only 
property missing was fluorescence. 
If the idea of quantum dot assembly into polypeptides by ribosomes was possible, 
 19
the following questions would have to be answered: 
1. Can large quantities of aminoacyl-tRNA modified by inorganic nano- 
materials be prepared?  
2. Can a ribosome translate an inorganic modified aminoacyl-tRNA?  
3. Will the inorganic modified amino acid residue be incorporated success-
fully into proteins?  


















2.1. INTRODUCTION  
 
Ribosomes are molecular machines that catalyze the assembly of amino acids into 
polypeptides according to the information encoded in an mRNA template using 
aminoacylated transfer RNAs (aa-tRNA) as substrates.   
The first system tested was modified lysyl-tRNA.  The reason for this choice 
was the availability and the high reactivity of the primary ε-amine contains in the side 
chain of lysine.[31-41, 106]  Lysine residues are often at the protein's surface, due to 
hydrophilic character, and allow a better visualization of quantum dots attached to its ε-
amino group.   The amino acylation and modification of lysyl-tRNA has been well 
developed.[107]  The scheme in Figure 2.1 outlines two methods for modification of 
lysyl-tRNA.  A heterobifunctional cross linker may be covalently attached to the ε-
amino group and then the quantum dot covalently attached or the quantum dot may be 
directly linked to the side chain to yield the formation of a new unnatural aminoacyl-
tRNA containing inorganic nanomaterials Inaa-tRNA).  The inorganic nanoparticle 
labeled aminoacyl-tRNAs will be used in an in vitro translation system to arrange the 
quantum dots according to the mRNA template.   
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Figure 2.1.  Two methods of preparation of gold nanoparticle •lysyl tRNAlys.   
A lysine specific tRNAlys is aminoacylated with lysine to yield the formation of 
lysyl- tRNAlys (see Figure 2, step 1), a heterobifunctional cross linker was covalently 
attached to the side chains of amino acid (see Figure 2, step 2).  Ultimately, gold 
nanoparticles, 1.4 nm mono-sulfo-NHS nanogold, were attached to the linker molecule or 









2.2. MATERIALS AND METHODS 
2.2.1 Enzymes: 
2.2.1.1. E. coli HisN-LysRS: 
The ORF encoding the E. coli hisN-LysRS was amplified from genomic DNA 
template using gene specific primers designed with BamHI and NdeI restriction sites at 
the 5’ and 3’ ends respectively.   The resulting amplified product was digested with 
BamHI and Nde I, separated by agarose gel electrophoresis and purified from the gel.   
The purified DNA product was ligated into a BamI/NdeI digested plasmid (pET19b) and 
transformed into DH5a cells.   The resulting colonies were screened by PCR for the 
correct insert and sequenced to confirm the correct insert was obtained. 
The resulting plasmid was used to transform expression cells (E. coli BL21Star 
strain cells (Invitrogen, Carlsbad, CA)).  A single isolated colony was picked and grown 
overnight at 370C in a 4 x 50 mL LB [Luria -Bertani (LB) broth]   medium and 100 
µg/mL ampicillin.  The overnight cultures (50 mL) were used for the inoculation of four 
liters (4 x 1L) of LB medium /ampicillin (AMP) (100 µg/mL).  To each 1L of LB/AMP 
a 50 mL culture grown overnight was added.  The incubation was continued at 370C 
with continuous shaking.  The OD600 was read hourly and when it reached 
approximately 1.0, expression was induced with IPTG (isopropyl-1-thio-β-D-
galactopyranoside).  The final concentration of IPTG was 1.0 mM.  The incubation 
was continued at 370C for 3 hours.  The cells were harvested by centrifugation at 2500 x 
g for 20 minutes at 40C.  The cell pellet was removed and resuspended in 15 mL of lysis 
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8).  To the resuspended 
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mixture of the cells 100 mM PMSF (phenylmethylsulfonyl fluoride) and 22 mg of 
lysozyme were added.  The cells were gentle stirred for 30 minutes, followed by lysis 
with gentle sonication.  The lysed cells were centrifuged at 14,000 x g for 45 minutes 
and the supernatant was collected.  The E. coli hisN-LysRS was purified using a nickel-
nitrilotriacetic acid resin (Ni-NTA) (QIAGEN, Valencia, CA) according to the 
manufacturer’s instructions.  A 2 ml column was washed with 10 mL water and 20 ml 
equilibration buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8).  The 
extract (30mL) was loaded onto the column and the column was washed with 100 mL of 
wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8).  The lysyl 
synthetase was eluted with a step gradient from 50 mM to 400 mM imidazole.  The 1 
mL fractions (12-40) containing the largest amount of protein were pooled together and 
dialyzed against 20 mM NaH2PO4 pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 
50% glycerol, and stored in 200 µL aliquots at -20°C.  The yield was approximately 150 
mg of protein and after dialysis the concentration of E. coli hisN-LysRS was ~20 mg/ml.  
The protein was soluble but was inactive. 
2.2.1.2. E. coli HisC-LysRS: 
The ORF encoding the E. coli hisC-LysRS was amplified from genomic DNA 
template using gene specific primers designed with XhoI and NdeI restriction sites at the 
5’ and 3’ ends respectively.   The resulting amplified product was digested with XhoI 
and Nde I, separated by agarose gel electrophoresis and purified from the gel.   The 
purified DNA product was ligated into a XhoI/NdeI digested plasmid (pET22b) and 
transformed into DH5a cells.   The resulting colonies were screened by PCR for the 
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correct insert and sequenced to confirm the correct insert was obtained. 
The resulting plasmid was used to transform expression cells (E. coli BL21Star 
strain cells (Invitrogen, Carlsbad, CA)).  A single isolated colony was picked and grown 
overnight at 370C in a 4 x 50 mL LB [Luria -Bertani (LB) broth]   medium and 
100µg/mL ampicillin.  The overnight cultures (50 mL) were used for the inoculation of 
four liters (4 x 1L) of LB medium /ampicillin (AMP) (100 µg/mL).  To each 1L of 
LB/AMP a 50 mL culture grown overnight was added.  The incubation was continued at 
370C with continuous shaking.  The OD600 was read hourly and when it reached 
approximately 1.0, expression was induced with IPTG (isopropyl-1-thio-β-D-
galactopyranoside).  The final concentration of IPTG was 1.0 mM.  The incubation 
was continued at 370C for 3 hours.  The cells were harvested by centrifugation at 2500 x 
g for 20 minutes at 40C.  The cell pellet was removed and resuspended in 15 mL of lysis 
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8).  To the resuspended 
mixture of the cells 100 mM PMSF (phenylmethylsulfonyl fluoride) and 22 mg of 
lysozyme were added.  The cells were gentle stirred for 30 minutes, followed by lysis 
with gentle sonication.  The lysed cells were centrifuged at 14,000 x g for 45 minutes 
and the supernatant was collected.  The E. coli  hisN-LysRS was purified using a 
nickel-nitrilotriacetic acid resin (Ni-NTA) (QIAGEN, Valencia, CA) according to the 
manufacturer’s instructions.  A 2 ml column was 10 mL washed with water and 20 mL 
equilibration buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8).  The 
extract (30mL) was loaded onto the column and the column was washed with 100 mL of 
wash buffer (50mM NaH2PO4, 300mM NaCl, 20 mM imidazole, pH 8).  The lysyl 
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synthetase was eluted with a step gradient from 50 mM to 400 mM imidazole.  The 1 
mL fractions (12-40) containing the largest amount of protein were pooled together and 
dialyzed against 20 mM NaH2PO4 pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 
50% glycerol, and stored in 200 µL aliquots at -20°C.  The yield was approximately 150 
mg of protein and after dialysis the concentration of E. coli  hisC-LysRS was ~25 mg/ml.   
The protein was soluble but was inactive.  Also, a different method of purification of E. 
coli  hisC-LysRS was performed and the protocol was reported by Ueda and his 
coworkers.[108]  
2.2.1.3. Human HisN-LysRS:  
Human lysyl-tRNA synthetase-histidine (pM368) tagged at the N terminus 
(Human His-LysRS) were generously provided by Prof.  Dr. Karin Musier-Forsyth of 
the University of Minnesota.  The preparation and purification were carried out as 
previously described.[107]  The plasmid pM368 was transformed in expression cells, E. 
coli  BL21 (DE3) (Novagen, Madison, WI) and a single isolated colony was grown 
overnight in a 4 x 50 mL LB medium and 100 µg/mL ampicillin.  The overnight 
cultures (50 mL) were used for the inoculation of four liters (4 x 1L) of LB medium 
/ampicillin (AMP) (100 µg/mL).  To each 1L of LB/AMP a 50 mL culture grown 
overnight was added.  The inoculation was continued at 370C under continuous shaking.  
The OD600 was read hourly and when it reached approximately 0.15, upon which the 
temperature was changed to 200C, and IPTG was added.   The final concentration of 
IPTG was 0.1 mM.  The incubation was continued at 200C for approximately 6 hours.  
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The rest of the steps were performed at 40C.  The cells were harvested by centrifugation 
at 2500 x g for 20 minutes.  The cell pellet was removed and resuspended in 15 mL of 
lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8).  The rest of the 
steps were identical with the ones performed for E. coli  hisN-LysRS. 
2.2.2. Transfer RNA  
 
The tRNALys gene in pUC19 was a gift from Dr. Karin Musier-Forsyth 
(University of Minnesota).  Large quantities of the plasmid were prepared by cesium 
chloride preps.    
Digestion of the plasmid with BstNI generates a linear template with the 
appropriate –CCA end for the tRNA to be aminoacylated.   The plasmid contains 
several BstNI sites; however, this does not interfere with in vitro transcription.  The 
linearized template (0.36-0.5 mg/mL final concentration) was transcribed using a T7-
MegashortscriptTM high yield transcription kit (Ambion, Austin, TX).   Briefly, the 
reaction contains linearized template, NTPs, buffer provided by the manufacturer and a 
mixture of T7 RNA polymerase and placental RNAse inhibitors.    
Initially, the tRNALys was purified using a Sephadex G-50 column (10 cc) and 
eluted with HE150 buffer (20 mM HEPES-KOH, pH 7.5, 10 mM EDTA, and 150 mM 
KCl).  The recovered tRNALys was precipitated using cold ethanol and 200 mM 
NH4OAc pH 7.5.   The tRNA was then purified using denaturing 6% polyacrylamide-
urea gel electrophoresis, and recovered by electroelution in sterile 1x TBE using a 
BioRad Electro-eluder apparatus( model 422).  The gel slice was placed into a glass tube 
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modified with glass frits and filled with sterile buffer.  A silicon adaptor with the 
membrane cap (which was pretreated by boiling for 1 hour at 600C in 1x TBE; the 
dialysis membrane is a 3,500 MW cut off) was fitted onto the bottom of the glass tube.  
The electro-elution was done at 10 mA for 3-5 hour.  At the end of elution the polarity 
was reversed (1-2 minutes to remove the tRNA from the membrane).  All the elution 
steps were done at room temperature.  All components were autoclaved in 1x TBE 
buffer to have an RNAse free system, except the plastic case, to prevent nuclease 
contamination.  The plastic case was treated with RnaseZap (Ambion).   The tRNALys 
recovered in the electroelution buffer was precipitated with ethanol in the presence of 
200mM ammonium acetate pH 7.5.  All the steps were performed at 40C if not stated 
otherwise. 






The reaction mixtures contained in 40 µL 100 mM Tris-HCl (pH 7.5), 5 mM magnesium 
acetate, 10 mM potassium chloride, 3.75 mM DTT, 3 mM ATP, 0.32 µM L-[14C]   
lysine (309mCi/mmol) (NENTM Life Science Products, Boston, MA) or 0.1 mM L-lysine 
(Aldrich), tRNALys (140pmol/reaction), and purified E. coli or human lysyl-tRNA 
synthetase (1 µg/µL).  The reactions were incubated at 370C for 15 minutes.  To 
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quantitate the incorporation of [14C]   lysine onto tRNALys, cold 10% TCA was added, 
and the resulting precipitate was collected onto glass fiber filters (Schleicher & Schuler, 
Germany).  The radioactivity on the filters was measured using a liquid scintillation 
counter.   The reactions that show significant incorporation of [14C]   lysine were 
phenol extracted and precipitated with ethanol and 200mM ammonium acetate pH 7.5.   
2.2.4. Coupled Transcription-Aminoacylation Reactions 
 
Coupled transcription-aminoacylation reactions were carried out in 40 µL or 100 
µL volumes.  The Ambion T7 Mega Shortscript transcription kit was used and the 
reaction supplemented with 2-4 µL lysyl-tRNA synthetase (1 µg/µL) and 75 mM [32P]-
UTP (0.05 mCi/mmol, to monitor RNA synthesis) or 0.32 µM L-[14C]   lysine (309 
mCi/mmol, to monitor aminoacylation).  The reactions were incubated at 370C for 135 
minutes.  Aliquots of 10 µL were collected at different times (0, 60, 90,120,135 
minutes), and precipitated with cold 10% TCA to determine the incorporation of 
radioactivity.    
The lysyl-tRNA (100 µL) was purified using ethanol precipitation in the presence 






2.2.5. Attachment of Cross-Linker [6-aminohexanoic acid (L2)] to lysyl-tRNA 
 
The attachment of 6-aminohexanoic acid to lysyl-tRNAlys was performed 
following the protocol from the manufacturer (Pierce Chemical, Co).[31, 109]  The only 
change to the procedure was that the reaction between EDC (1-ethyl-3- (3-
dimethylaminopropyl) carboiimide), NHS (N-hydroxysuccinimide), and 6-
aminohexanoic acid (L2) was performed in a higher concentration (2 M EDC, 5 M NHS 
and 2 M L2) than the one suggested (2 mM EDC, 5 mM NHS and 2 mM L2).  The 
reaction was stirred overnight at room temperature instead of the suggested 1 hour to 
increase the final product yield.  The final product, N-hydroxysuccinimidyl-6-
aminohexanoate, was reacted with lysyl-tRNA.  The modified lysyl-tRNA (Nε-NHS-L2-
lys-tRNA) was precipitated as described above (cold ethanol and 200 mM NH4OAc pH 
7.5).  All the steps were performed at 40C if not stated otherwise.  A duplicate set of 
reactions using L- [14C]   lysine (309 mCi/mmol) were run as controls to be able to 
monitor the aminoacylation state during the modification steps.   
2.2.6. Attachment of nanogold to lysyl-tRNA or linker- lysyl-tRNA 
 
The attachment of the 1.4-nm mono-sulfo- succinimido-nanogold (Nanoprobes, 
Yaphank, NY) to tRNA was performed using methods modified from the manufacturer's 
instructions.  The lysyl-tRNA (1.5 nmoles) or Nε-NHS-L2-lysyl-tRNA (1 nmoles) were 
ethanol precipitated overnight and collected by centrifugation at 10,000 x g for 15 
minutes.  The pellets were resuspended in 20 mM HEPES-KOH (pH 7.5), and 5 nmoles 
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of gold particles resuspended in water were added.  The reaction was stirred for one 
hour and left overnight on ice.  The gold-lysyl-tRNA and gold-L2-lysyl-tRNA were then 
ethanol precipitated in the presence of 200 mM ammonium acetate pH 7.5, and the gold-
tRNA complexes were purified from unreacted gold particles using a Micro Bio-Spin 6 
column (BioRad, Hercules, CA).  A duplicate set of reactions using L-[14C]   lysine 
(309 mCi/mmol) were run as controls to monitor the aminoacylation state.   
2.2.7. Coupled Transcription/Translation 
 
The translation reactions were performed, as was previously described.[110] An E. coli 
S30 fraction and reagents was generously provided by Dr. Gisela Kramer, The University 
of Texas at Austin.  The translation reaction contained in 30 µL; 5 µL of the E. coli  
S30 fraction, 55 mM Tris-acetate (pH 7.8), 2 mM DTT, 1 mM ATP, 0.8 mM each GTP, 
CTP,and UTP, 2% poly(ethy1ene glycol)-6000, 25 mM phosphoenol pyruvate, 0.4 mM 
CAMP, 3 6 mM NH3OAC7, 2 mM KOAc, 16 mM Mg(OAc)2, 0.5 mM EDTA, 1 µg of 
the pGEM-3z plasmid as template (contains the infC gene, the E. coli  gene for initiation 
factor 3 (IF3) and has 21 lysines), 0.33 µM of leucine, 0.83µM all the amno 
acids( minus-leucine and lysine) and 0.069 µM of the Au•[14C]   lysyl-tRNA or L-[14C]   
lysyl-tRNA ([14C]lysyl-tRNA).  The reactions were incubated at 370C for 30 minutes, 
stopped by the addition of 100 µL of 1M NaOH, and incubated for an extra 5 minutes at 
370C to degrade the tRNA.  Aliquots of 5 µL were precipitated with 5% TCA and the 
incorporation of radiolabled lysine was determined by scintillation counting. 
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2.3 RESULTS AND DISCUSSIONS: 
 
The E. coli  lysyl-tRNA synthetase is encoded in two different genes LysS 
(constitutive) and LysU (thermoinducible) which yield the formation of two isoforms of 
the enzyme.[111]  Brick and his coworkers reported in 1995 the structure of E. coli 
LysRS-LysU.[112]  They found that the protein is a dimer and the N-terminal domains 
are involved in the binding of the tRNA anticodon domain and the C-terminal domain is 
the catalytic domain characteristic for all the enzymes from class II synthetases.[112]  
The lysyl-tRNA synthetase is recognized by the tRNALys through the anticodon triplet 
(UUU) [111, 113], the “discriminator” base A73 [107, 114] and through the acceptor 
stem.[115] 
Preparation of E. coli tRNAlys .The E. coli lysine specific tRNA (tRNAlys) was 
encoded on plasmids, containing a T7 promoter and generously provided by Dr. Karin 
Musier-Forsyth of the University of Minnesota.   The tRNAlys gene was constructed to 
have the restriction enzyme site for BstN I (5’…CCAGG…3’).   Linearization of the 
plasmid with BstN I yielded the required ...GGT 3’ end template to generate the CCA3” 
end of the tRNA required for aminoacylation of the tRNA by the lysine synthetase.  
Large amounts of purified plasmid are easily prepared and used as template for in vitro 
transcription by T7 polymerase.  A typical 0.5-1.0 ml transcription reaction yielded 1-3 
mg of tRNAslys (see Figure 2.2).  The tRNAslys was purified using column 
chromatography; gel electrophoresis and electroelution (see materials and methods). 
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Figure 2.2.   Purification of in vitro synthesized E. coli lysine specific tRNAlys.   
A.  The in vitro synthesized tRNAlys was purified using a G-50 Sephadex column.  
Fractions of 1 ml were collected and aliquots of 10 µL were run on a 2% agarose gel in 
TBE.  B.  Urea Gel Analysis of tRNA.  Aliquots of 9µg of in vitro synthesized lysine 
specific tRNAlys (T) and native E. coli lysine specific tRNAlys (N) (Sigma) were mixed 
with an equal amount of 10X urea-gel dye.   The samples were separated on a 6% urea 
acrylamide gel.   The tRNA was visualized with 0.1% Stains-All (Sigma) and the gel 
dried.     
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 Preparation of E. coli lysyl-tRNA synthetase.   The plasmid which encodes 
E. coli lysyl-tRNA synthetase was a gift from Dr. Karin Musier-Forsyth (University of 
Minnesota).  The E. coli lysyl-tRNA synthetase, that was histidine tagged at the N-
terminal or C- terminal were prepared and purified as described in materials and methods.    
Aminoacylation of E. coli tRNAlys by E. coli lysyl-tRNA synthetase.  The 
established method of amino acylation of tRNA is to use purified tRNA and aminoacylate 
the tRNA with the respective synthetase in the presence of the cognate amino acid and 
ATP.[114, 116]   However, the yields for the charging of E. coli tRNAlys with E. coli 
synthetase were quite low (aminoacylation yields were approximately 10-20 %).  All the 
assays conducted with E. coli HisN-LysRS, showed that the synthetase is not active and 
failed to charge.  A C-terminal histidine tagged E. coli HisC-LysRS, was prepared and 
purified.[108]   The aminoacylation assay carried out using E. coli HisC-LysRS, also 
failed to aminoacylate the in vitro synthesized tRNALys to a satisfactory level.  To prove 
the poor activity of the E. coli lysyl synthetases was due to the unmodified transcribed 
tRNA and not the activity of the expressed protein, native yeast and/or E. coli total tRNA 
mixture were used as substrates.  Using the E. coli lysyl-synthetases with the yeast total 
tRNA gave an estimated yield of 45% aminoacylation assuming that the tRNAlys is at 
least 1/20 of the tRNA population.  One can conclude that the modified nucleotides 
[107] are essential for charging E. coli tRNAlys efficiently and that the E. coli synthetases 
are unsatisfactory for preparing large amounts of aminoacylated tRNA( prepared by in 
vitro transcription) for labeling with nanoparticles and/or quantum dots.  However, 
human lysyl-tRNA synthetase (Human LysRS) does not have the requirement for post 
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transcriptional modification of the tRNA. 
Preparation of the Human lysyl-tRNA synthease.   The plasmid which 
encodes human lysyl-tRNA synthetase was a gift from Dr. Karin Musier-Forsyth 
(University of Minnesota) and was prepared and purified as described in Materials and 
Methods.  The expression of the human enzyme in E. coli was very low and the yield of 
enzyme was very low compared to the E. coli lysyl-synthetase. 
Aminoacylation of E. coli tRNAlys by human lysyl-tRNA synthetase.  The 
aminoacylation of the in vitro transcribed E. coli tRNAlys was considerably better with 
the human synthetase than with the E. coli.  The yield of the aminoacylation reaction for 
human LysRS was approximately 35 to 50%.  As shown in Table 2.1 the yields of 
aminoacylation depend on the amount of human LysRS and on the source of lysine 
specific tRNALys.  The native lysine specific tRNA was not aminoacylated in presence 
of human LysRS showing that the synthetase recognizes only the in vitro synthesized 
tRNAlys.   
Table 2.1.  Comparison of aminoacylation between the native and in vitro 
synthesized lysine specific tRNAlys. 














In vitro 112 3 51 45 
In vitro 112 6 60 53 
In vitro 112 12 81 72 
Native 112 3 1 0.93 
Native 112 6 1.34 1.26 




Figure 2.3.  Coupled Transcription-Aminoacylation for lysine specific tRNAlys  
 
Development of a new method for preparation of aminoacylated tRNA.    
One of the goals set forth was to prepare large amounts of nanoparticles and/or quantum 
dots labeled tRNA.  The established method of in vitro preparation of tRNA involved 
gel purification, elution from the gel, phenol extraction and ethanol precipitation prior to 
aminoacylation.   All of these steps caused losses of the tRNA, presented opportunities 
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for RNAase contamination and degradation and required renaturation of the RNA by 
heating/cooling.   
To improve the efficiency of the process, the human lysyl synthetase was added 
directly to the in vitro transcription assay.  Thus, the tRNA would be aminoacylated as 
soon as it was transcribed and folded correctly.  This novel method was called “coupled 
transcription aminoacylation” or CTA.  For the monitoring of the coupled transcription–
aminoacylation reactions, radiolabeled α-[32P] UTP and the L-[14C] lysine were used, and 
their incorporation was monitored over a time course shown in Figure 2.4 and 
summarized in Table 2.2 and Figure 2.4. 
 
Table 2.2. Quantitative incorporation of radiolabeled UTP and lysine in tRNA at 
different time frames  
 







0 0 0 0 
30 102 74 72.5 
60 110 87 79 




Figure 2.4.  Incorporation of radiolabeled [32P] UTP and [14C] lysine in tRNAlys 
within the two-hour period . 
Time course of incorporation of α-[32P] UTP (54 dpm/pmol) into lysine specific 
tRNAlys (♦) and [14C] lysine into [14C]lys-tRNAlys ( )(682 dpm/pmol).   Aliquots of 10 
µL were removed at indicated times and precipitated with cold 10% trichloroacetic acid 
and collected on glass fiber filters by vacuum filtration.[117]   The filters were dried 
and counted in a scintillation counter (Beckman) and the amount of tRNA synthesized or 
aminoacylated was calculated. 
 
 
The increase in both [32P] UTP and [14C] lysine shows the efficiency of both the 
tRNALys synthesis and the aminoacylation reaction.  It appears that the aminoacylation 
of tRNALys occurs rapidly after the tRNA is transcribed and presumably folds correctly.  
The yields of aminoacylation in these reactions were around 50 - 60%.  The CTA 
method was used later for the cysteine system and it generated large amounts of 
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aminoacylated tRNA.[118] 
Electrospray ionization mass spectroscopy (ESI-MS) was used to verify that 
lysyl-tRNA is formed (Figure 2.5).  In the ESI-MS spectrum two peaks were expected, 













Figure 2.5.   ESI-MS of a mixture of lysine specific tRNA (24630) and lysyl-tRNA 
(24754).   
An aliquot of 3 nmols of a mixture of lysine specific tRNAlys and lysyl-tRNAlys 
was purified using phenol extraction and ethanol precipitation.  The salt used in ethanol 
precipitation was 200 mM NH4OAc pH 7.5. 






 Attachment of Nanogold to lysyl-tRNAlys.    The next step was the attachment 
of a heterobifunctional cross linker to the aminoacylated tRNA and then to the Nanogold 
(see Figure 1.2, step 2).  A heterobifunctional cross linker is a reagent which has two 
different functional groups, each reactive towards two different functional target.  The 
chosen heterobifunctional linkers for the lysine system have one functional group (i.e. -
COOH) reactive towards an amine group and the other functional group (i.e. -NH2) is 
reactive towards a carboxylic group. The heterobifunctional linkers used are the 11-
aminoundecanoic acids (L1) and the 6-aminohexanoic acid (L2).  The 6-aminohexanoic 
acid reacted with N-hydroxysuccinimide in the presence of EDC to yield the NHS ester 
of the target linker.  The NHS ester reacted with the lysyl-tRNA and the linker is 
covalently attached to the ε-amine group.  The ε-amine group is more reactive than the 
α-amine group (the ratio is approximately 97:1) most likely due to steric impediments 
(the size and folding of the tRNA plays an important role).[31, 33-36, 106] However, it 
has been reported that the NHS ester of the linker may react with the α-amino group 
which would prevent the incorporation of modified lysine residues into proteins.[31] 
The remaining free reactive group of the linker was reacted with gold 
nanoparticles to yield a novel gold nanoparticle-conjugated-L-aa-tRNA (See Figure 1.2, 
step3).  For the lysine system 1.4 nm mono-sulfo-NHS nanogold was used and it was 
purchased from Nanoprobes, Inc.  The nanogold compound has a single reactive group 
on the surface, a sulfo-N-hydroxysuccinimide ester (sulfo-NHS), which is very reactive 
towards primary amines under mild conditions (pH 7.5).  A covalent attachment of the 
nanogold to the free epsilon amino group on the linker was obtained.   An alternative 
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approach was to eliminate the bifunctional linker and to attach the gold nanoparticle 
directly to the side chain of the lysine, (see Figure 2.1, step 2’).  The conditions used for 
direct linkage were the same as the ones used in the presence of a linker and in both 
experiments a unique nanogold-tRNA complex was obtained.  The successful 
attachment of nanogold to lysyl-tRNA in the absence or presence of a linker was verified 











Figure 2.6.  ESI-MS on nanocrystal tRNA complex (Au•Lys-tRNA). 
An aliquot of 1 nmols of lysyl-tRNAlys modified with 1.4 nm mono-sulfo-NHS nanogold 




Figure 2.7.  MALDI-MS on nanocrystal tRNA complex (Au•L2Lys-tRNAlys).   
An aliquot of 300 pmol of gold modified L2lysyl-tRNAlys was mixed with 2, 4, 5-
Trihydroxyacetophenone monohydrate (THAP) in acetone and ammonium citrate.  The 
mixture was crystallized on a MALDI grid.  The Lysyl-tRNAlys was modified with 6-
aminohexanoic acid (L2) and subsequently modified with 1.4 nm mono-sulfo-NHS 
nanogold to yield the formation of Au•L2Lys-tRNAlys.  The Au•L2Lys-tRNAlys was 
ethanol precipitation.  The salt used in ethanol precipitation was 200 mM NH4OAc pH 
7.5. 
 Table 2.3.  Mass spectroscopy theoretical and experimental data for lysine specific 











tRNALys 24659.2 24693.7 24647 
24631(mix) 
24687.4 
Lys-tRNA  24822 24751  
Au Lys-tRNA   44116  









The molecular weight difference presented in the spectra for the gold nanoparticle 
modified lysyl-tRNA in the absence or presence of a linker (see figure 2.4 and 2.5) is due 
to variations in the molecular weight of the gold nanoparticles (approximately 15, 000Da 
as indicated by the manufacturer) and is dependent on the number of gold atoms present 
in the nanoparticle clusters (76-100 gold atoms/nanoparticle).   
Further analysis of the Au-modified tRNA by TEM (see Figure 2.8) showed that 
the dimension of the gold nanocluster was in good agreement (~1.7 nm) with the reported 
size (1.4 nm).   
   These results were very encouraging and suggested that a gold nanoparticle could be 
successfully attached to an aminoacyl-tRNA.   
 
Figure 2.8.  TEM image of nanogold particles attach to ε-amine of a lysyl-tRNA.  
An aliquot of 500 pmols of nanogold modified lysyl-tRNAlys purified on a 
G-25 Sephadex column to remove unbound gold nanoparticles, were spotted 
on a cooper grid coated with a continuous carbon thin film. 
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In vitro translation with Au•Lys-tRNA.   The ability of the novel quantum 
dot-conjugated-L-aa-tRNA to be incorporated into a polypeptide was measured using an 
E. coli  cell-free coupled transcription-translation system.[110]  The translation system 
consists of an extract from E. coli (S30) that contains ribosomes, all the enzymes 
necessary for translation, the tRNAs with their respective synthetases, but is depleted of 
endogenous mRNA and small molecules (e.g. amino acids, NTP).  The reaction mixture 
containing the E. coli extract is supplemented with T7 RNA polymerase to transcribe the 
desired mRNA from a plasmid.  Dr.Gisela Kramer (The University of Texas at Austin) 
kindly provided the E. coli extract and T7 polymerase for these experiments.  The E. 
coli extract is depleted of amino acids and small molecules during preparation.  When 
the translation is performed, the amino acids and NTPs must be added to the reaction 
mixture.  The amino acid corresponding to the radioactive label, in this case lysine, is 
omitted and the remaining 19 amino acids are added to the reaction mixture.    
To test the ability of the Au•[14C]lys-tRNA to function in translation was 
measured.  The DNA plasmid used for the template for a mRNA encodes E. coli 
translation initiation factor (IF3) and the protein product has 21 lysine residues.  The 
amount of radioactivity incorporated into protein was measured by precipitation using 
trichloroacetic acid (TCA).  The amount of [14 C] lysine incorporated was similar (10-15 
pmols) for [14C] lysyl-tRNA or Au•[14C] lysyl-tRNA.  In the absence of added template 
the amount of [14C] lysine incorporated was about 5 pmols.   This result suggested that 
the gold nanoparticles do not inhibit the translation but the amount of translation was 
very low.   
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The incorporation of quantum dots into the polypeptides was analyzed by 
electrophoresis (SDS-PAGE), and electron microscopy (TEM).  In the SDS-PAGE gels 
no full length product was observed; however, the TCA analysis suggests that small 
peptides may have been synthesized.  The transmission electron microscopy (TEM) 
analysis was unsuccessful due to the high organic background present in the samples.  
We did not have the means to purify the full length protein or the small peptides from the 



















The binding of gold nanoparticle to the lysyl-tRNA (in presence or absence of the 
linker) demonstrates the viability of interaction between two very different and complex 
systems, and opens new opportunities for the interactions of similar systems. 
Despite initial promising results with the lysine system, it was abandoned for 
multiple reasons.  The detection of the L-[14C] lysine required long exposure times to a 
phosphorimager screen and the [14C] lysine is very expensive.  The second reason was 
the poor expression and stability of human lysyl-tRNA synthetase (human LysRS).  
From 14 batches only two of them were active and the yield of protein expressed was 
very low.  The third reason was the aminoacylation of the in vitro synthesizes lysine 
specific tRNA failed when C- and/or N-terminal histidine tagged E. coli tRNA-
synthetases were used.  The presence of the modified nucleotides in tRNA is necessary 
for enhanced aminoacylation.    
Another tRNA/synthetase pair was sought that would have a more robust 
synthetase and not require modification of the tRNA for aminoacylation.  The amino 
acid would need to have a reactive side chain.   The best candidate for additional 







3.1. WHY WE CHOOSE THIS SYSTEM VERSUS LYSINE OR OTHER AMINO ACIDS 
SYSTEMS 
 
The cysteine system was chosen for several reasons:  
(1) The E. coli cysteinyl-tRNA synthetase/tRNA pair does not require the base 
modification for an efficient aminoacylation and has been extensively studied by Dr. Ya-
Ming Hou’s group.[19-21, 23-29, 120-122] 
(2) L-[35S] cysteine would allow for faster visualization of the products (aminoacylated 
tRNA, translated proteins) and is considerably less expensive.  One of the conclusions 
from the work on the lysine system was necessary to quickly visualize the products from 
the intermediate steps.  All the intermediate steps in the preparation of the gold 
nanoparticle modified tRNA are labile and light sensitive. 
(3) The cysteine has only one reactive site (SH-) compared to lysine (two amino groups). 
(4) Cysteine also has a relatively low distribution in proteins (an average of 1-6 cysteine 
residues per protein) which implies that a high concentration of modified cys-tRNA 
would not be as critical in the in vitro translation reactions compared to the lysine system.   
(5) The sulfhydryl group in the beta position of the cysteine side chain presents the 
possibility of modifying proteins with a variety of cross–linked labels and nanoparticles.  
In particular the gold nanoparticles available in the <2 nm range are modified with a 
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single monomaleimido group.  The chemistry between sulfhydryl group and 
monomaleimido group is well known and intensively studied.[72, 123, 124] 
 
For the reasons mentioned above, the cysteine system was chosen for 
demonstrating the concept that a molecular machine (ribosome) could accommodate an 
inorganic material without terminating translation and would incorporate inorganically 
modified cysteine into a protein to create novel nanoscale inorganic/biological materials.  
This would show that the ribosome could function to assemble novel inorganically 
modified peptide based materials (see Figure 3.1).  This method makes it possible to 
imagine supramolecular assembly of novel bioinorganic heterostructures using the 
ribosome.   
The research described in this chapter is: (1) in vitro synthesis and aminoacylation 
of the cysteine specific tRNAcys (see Figure 3.2, step 1); (2) attachment of gold 
nanoparticle (monomaleimido nanogold) to the sulfhydryl group present on the side chain 
of cysteine (see Figure 3.2, step 2); (3) incorporation of this new inorganically modified 
cysteinyl-tRNA in a coupled transcription-translation reaction to generate protein 
containing inorganic materials (see Figure 3.1).        
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Figure 3.1.  Model for the assembly of nanoparticles into proteins by molecular 
machines. 
Ribosomes are molecular machines that catalyze the assembly of amino acids into 
polypeptides according to the information encoded in an mRNA template using 
aminoacylated transfer RNAs (aa-tRNA) as substrates.  The tRNA molecules are 
specific to their cognate amino acids and deliver amino acids to the ribosome.   An 
aminoacylated tRNAcys (cys-tRNAcys) may be modified by attaching a nanogold particle 
to the sulfhydryl group of the amino acid.  This inorganically modified aminoacylated 
tRNAcys (Au cys-tRNAcys) delivers the nanogold modified amino acid to the molecular 
assembly machine (ribosome).  The molecular machine uses the inorganically modified 
tRNA to assemble a hybrid protein containing nanogold wherever cysteine is specified by 
the mRNA.  Ultimately, this pioneering method may be used to assemble novel bio-
inorganic materials such as peptide nanowires. 
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3.2. MATERIALS AND METHODS 
 
3.2.1. E. coli HisC-CysRS:  
The plasmid pCysRS09 which encodes the gene for E. coli  HisC-CysRS was a 
generous gift from Dr. Y-M Hou (Thomas Jefferson University, Philadelphia, PA).[122] 
The recombinant DNA was used to transform the expression cells E. coli BL21Star 
(Invitrogen, Carlsbad, CA).  Single colonies were picked and grown overnight at 370C 
in a 4 x 50 mL LB [Luria -Bertani (LB) broth]   medium and 100 µg/mL ampicillin.   
Four flasks (4 x 1L) of LB medium /ampicillin (AMP) (100 µg/mL) were each inoculated 
with a 50 mL culture grown overnight.  The cultures were incubated at 370C under 
continuous shaking.  The OD600 was read hourly until it reached approximately 0.5-0.9, 
when it was induced with IPTG (isopropyl-1-thio-β-D-galactopyranoside) at a final 
concentration of 0.1 mM.  The incubation was continued at 370C for an additional 4 
hours.  The cells were harvested by centrifugation at 2500 x g for 20 minutes at 40C.  
The cell pellet was resuspended in 25 mL of lysis buffer (50 mM HEPES–KOH, pH 7.6, 
1 M NH4Cl, 10 mM MgCl2, 10 mM MgCl2, 0.3 mg/ml lysozyme, 0.1% Triton X-100, 0.2 
mM phenylmethylsulfonyl fluoride (PMSF), and 7 mM β-mercaptoethanol) and lysed by 
sonication.  The lysed cells were centrifuged at 100,000 x g for one hour and the 
supernatant was collected.  The E. coli HisC-CysRS was purified using a nickel-




3.2.2. Coupled Transcription-Aminoacylation (CTA)  
 
The plasmid containing the tRNAcys gene with a T7 promoter (250 µg) was 
digested with BstNI to linearize the template for transcription.  Plasmid pTFMa 
containing the tRNAcys gene was a generous gift from Dr. Y-M Hou (Thomas Jefferson 
University, Philadelphia, PA).[29]  The linearization reactions were performed at 370C 
for 18 hours.  Digestion with BstNI leaves a template for the 3’ CCA end of the 
transcribed tRNA.  T7-MegashortscriptTM transcription kits (Ambion, Austin, TX) were 
used according to the manufacturer’s instructions.  The digested template (0.36-0.5 
mg/mL the final concentration in the reaction) was transcribed in a 100 µL reaction 
mixture volume.   To couple the transcription and charging reactions, the mixture was 
supplemented with 6-12 µg purified E. coli cys-tRNAcys synthetase and either 75 mM 
[32P]-UTP (444 cpm/pmol), Perkin-Elmer Life and Analytical Sciences, Inc, Boston, MA 
to monitor tRNA formation or 1.2 mM L- [35S] cysteine (1000 cpm/pmol) (Perkin-Elmer 
Life and Analytical Sciences, Inc, Boston, MA) to monitor tRNA aminoacylation.  The 
reaction was incubated at 370C for 2 hours, and aliquots were taken at various time points 
and analyzed by electrophoresis on a 6% urea-acrylamide gel. 
Large scale synthesis of cys-tRNAcys (0.5 mL) was carried out as described 
above and supplemented with either [35S]-cysteine or unlabeled cysteine.   E. coli HisC-
CysRS was removed batchwise from the charged tRNA with nickel-nitrilotriacetic acid 
resin (Ni-NTA, QIAGEN, Valencia, CA).  The Ni-NTA matrix (200 µL) was washed 
twice in a 1.5 mL microcentrifuge tube with 500 µL of 20 mM HEPES-KOH pH=7.6.   
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The resin was allowed to settle and the supernatant removed.   The cys-tRNAcys was 
added to the matrix, gently mixed by rotation for 1 hour at 40C.  The mixture was then 
centrifuged for 1 minute to pellet the resin, and the supernatant containing the cys-
tRNAcys was removed.   This process was repeated as necessary to remove any 
remaining synthetase.  The cys-tRNAcys was purified by gel filtration on a Sephadex G-
25 column as previously described.[36]  The fractions containing the highest amount of 
cys-tRNAcys were pooled (~0.5 mL), lyophilized, and dissolved in 75 µL of H2O.   The 
yield from a 0.5 mL reaction was approximately 1-1.5 mg.  No phenol extraction, 
ethanol precipitation, gel filtration, or heating and reannealing were performed. 
 




3.2.3. Attachment of biotin [N-iodoacetyl-N-biotinhexylenediamine]   to cysteinyl-
tRNA 
 
The attachment of biotin [N -iodoacetyl-N-biotinhexylenediamine]   (ILCB) to 
[35S]-cysteinyl-tRNA was carried out according to the manufacturer's instructions (Pierce 
Biotechnology, Rockford, Il.).   Briefly, [35S] cysteinyl-tRNAcys (21 nmols) was 
incubated in the dark with ILCB (37.5 nmols) (2 mM ILCB resuspended in DMSO) for 2 
hours at room temperature and 2 hours at 40C.  The biotinylated cys-tRNAcys was 
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purified by Sephadex G-25 column chromatography as described above and lyophilized.    
3.2.4. Attachment of Monomaleimido Nanogold (MMA-Au) to cysteinyl-tRNA 
 
 The attachment of the 1.4nm monomaleido nanogold (Nanoprobes, Yaphank, 
NY) particle to [35S] cysteinyl-tRNA and/or cysteinyl-tRNA was carried out accordingly 
to the manufacturer instructions with slight modifications.  The purified cysteinyl-tRNA 
(30nmol) was resuspended in 20 mM sodium phosphate, 150 mM NaCl, 1mM EDTA, pH 
6.5 and added to monomaleimido nanogold (MMA-Au), 60 nmol in water.  The mixture 
was incubated at room temperature with rotation for 2 hours and for another 2 hours at 
40C.  The gold modified cysteinyl-tRNA was purified by Sephadex G-25 spin column 
chromatography and lyophilized.  The 1 cc. Sephadex G-25 spin columns are 
equilibrated with 2 column volumes of water and collected by centrifugation at 900rpm 
for two minutes.  The reaction mixtures (from 50 µL to no more then 125 µL per 
column) are added to the column and collected by centrifugation again at 900 rpm for 3-4 
minutes.   
3.2.5. In vitro Coupled Transcription-Translation reactions 
 
The E. coli  T7 S30 Extract System (Promega, Madison, WI) was used for 
coupled transcription/translation assays.   Plasmid pIVEX 2.1 encoding green 
fluorescent protein (GFP, Roche Applied Science, Indianapolis, In) was used as the 
template in the coupled transcription-translation reaction.  The reaction mixture was 
supplemented with 2 mM L-[35S] cysteine, 2 mM L-[35S]cys-tRNAcys, 2 mM ILCB-
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[35S]cys-tRNAcys, or 4 mM Au•[35S]cys-tRNA.  The biosynthesis of [35S]-GFP or 
modified [35S]-GFP was confirmed by SDS-PAGE and autoradiography.   The 
biosynthesis of biotinylated GFP was confirmed by SDS-PAGE, western blotting to a 
PVDF membrane, and detection using streptavidin-horseradish peroxidase conjugate 
(Pierce Biotechnology, Inc., Rockford, IL) and a chemiluminescent or colorimetric 
substrate (TMB) (Pierce Biotechnology, Inc., Rockford, IL).  The biosynthesis of Au-
GFP was confirmed by SDS-PAGE, western blotting to a PVDF membrane, and 
detection using laser ablation ICP-mass spectrometry (see below), 
 
An alternative method for detection of the protein products that eliminated the 
need for [35S]-cysteine was to include [14C]-leucine in the reaction mixture.  An amino 
acid mix (18 amino acids minus cysteine and minus leucine) was used for these reactions.  
The reaction mixture was supplemented with 2 mM cys-tRNAcys, 2 mM ILCB-cys-
tRNAcys, or 4-8 mM Au•Cys- tRNAcys (the higher concentration improves translation and 
provides excess Au to scavenge up excess DTT (~1-2 mM)) and 2 mM L-[14C]-leucine.  
The biosynthesis of [14C]-GFP or gold modified [14C]-GFP was confirmed by 
electrophoresis, autoradiography and LA-ICP MS.  The reactions containing gold 
modified [14C]-GFP and the no template control were further purified batchwise on a 
Strep-tactin matrix (IBA, Goettingen, Germany) according to the manufacturer’s 
instructions.  Strep –tactin matrix 10% v/v (5 µL matrix per 50 µL reaction) was washed 
tree times with the 50 µL washed buffer (100 mM Tris-HCl, 150 mM NaCl, 1 mM 
EDTA, pH 8).  After the wash buffer was removed completely the transcription-
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translation reaction was added to the matrix and rotated overnight at 40C.  Next day the 
supernatant was removed and the matrix was washed tree times with the 100 µL wash 
buffer.  The protein was eluted with 25 µL elution buffer (100 mM Tris-HCl, 150 mM 
NaCl, 1 mM EDTA, 2.5 mM desthiobiotin, pH 8).  The fractions containing the purified 
protein were analyzed by electrophoresis, autoradiography, LA-ICP MS and HAADF.   
3.2.5.1. Laser Ablation Inductively Coupled Plasma Mass Spectrometry-LA-ICP 
MS 
 
The tRNAcys samples were separated by electrophoresis on a 6% urea/acrylamide 
gel.   The gel was dried between two sheets of cellophane and cut in 3.00 cm strips.   
The strips were applied with double sided tape to 4.6 cm glass slides.   The protein 
samples were run on Novex 10-20% Tris –Glycine gel (Invitrogen) and transferred to a 
PVDF membrane.   The membrane was cut in strips (4.3 cm long and 1.2 cm wide) and 
similarly applied to a glass slide using a double sided sticky tape.   The glass slide and 
gel or membrane were placed in the ablation chamber and purged with helium.  Gold 
was monitored by the ICP-MS as the laser traversed down the center of the lane.  All the 
measuring conditions and the instrument settings used for LA-ICP MS are detailed in 






Table 3.1.  LA-ICP MS Measurement Conditions 
 
ICP-MS GVI Platform quadrupole ICP-MS 
RF power 1380 W 
Ar flow rates 
Cool 13.5 L min-1 
Auxilliary 1.20 L min-1 
Make-up gas 0.50 L min-1  
Hexapole collision/reaction cell 
He 5.5 mL min-1 
H2 5.0 mL min-1  
Data acquisition 
Scanning mode Peak hopping 
Dwell time 20 to 100 msec 
Inter Channel Delay 20 msec 
 
Laser ablation system New Wave LUV213 
 213 nm output, NdYAG laser source 
Spot diameter 400 µm 
Scan rate over transect 30 to 80 µm sec-1 
Run time 16 min-Au•cystRNA; 8.5 min-Au•GFP  
Repetition rate 10 sec-1 
Power setting 80 to 100% 
Energy 2.65 millijoules 
Fluence 2.11 j cm-2 
He flow rate through  0.80 to 0.90 liters min-1 







3.2.5.2. High Angle Annular Dark Field -HAADF.   
 
The samples for HAADF were prepared on a copper grid coated with a 
continuous carbon thin film (Ted Pella, Inc, Redding, CA.).   Samples of 3µL were 
added on top of the grid and dried at room temperature.  The HAADF images were 
collected with a JEOL 2010F transmission electron microscope in STEM mode, using a 
HAADF detector equipped with an Oxford energy dispersive spectroscopy unit.  The 

















3.3. RESULTS AND DISCUSSION: 
 
Preparation of Cysteinyl-tRNA.  The preparation of the cysteinyl tRNA was similar to 
the lysine system.  The coupled transcription and aminoacylation reaction was used to 
by-pass all the intermediate purification steps.  Similar results were obtained with the 
cysteine system as obtained in the lysine system.  
The time course of cysteine-specific tRNAcys synthesis in an in vitro transcription 
and a CTA reaction is shown in Figure 3.3.  To quantify the amount of synthesized 
tRNAcys, radiolabeled α- [32P] UTP was added to the reaction mixture (see Figure 3.3.B).    
Transcription products in both reaction mixtures increased over the time course; however, 
transcription in the CTA reaction mixture was reduced ~25% at later time points (see 
Figure 3.3.C).  This may be due to consumption of ATP during aminoacylation, 
reducing transcription efficiency.  An additional experiment was performed where an 
excess of ATP was added to the reaction mixture.   An increase in the yield of tRNAcys 








Figure 3.3.  Time course of in vitro synthesis of [32P] tRNAcys (transcription) and 
cys-[32P] tRNAcys (CTA).   
A.  Aliquots of 2.5 µL were removed at indicated times and mixed with an equal amount 
of 10X urea-gel dye.  The samples were loaded on a 6% urea acrylamide gel.  The gel 
was stained with 0.1% Stains-All (Sigma) and dried.  B.  The gel shown in panel A.  
was exposed to a phosphorimager screen to visualize the incorporation of α-[32P] UTP 
(54 dpm) in cysteine specific tRNAcys (transcription) and cys-tRNAcys (CTA).    C.  
Time course of incorporation of α-[32P] UTP (54 dpm) into cysteine specific tRNAcys ( ) 
and cys-tRNAcys ( ).   Aliquots of 5 µL were removed at indicated times and 
precipitated with cold 10% trichloroacetic acid and collected on glass fiber filters by 
vacuum filtration.[117]  The filters were dried and counted in a scintillation counter 
(Beckman) and the amount of tRNA synthesized calculated.  The ratio of transcript 






Figure 3.4.  Time course of in vitro synthesis of [35S]cys-tRNAcys. 
A.  Aliquots of 2.5 µL were removed at indicated times and mixed with an equal amount 
of 10 X urea-gel dye.  The samples were loaded on a 6% urea acrylamide gel.  The gel 
was stained with 0.1% Stains-All (Sigma) and dried.  B.  The gel in panel A was 
exposed to a phosphorimager screen (Amersham Biosciences, Piscataway, NJ) to 
visualize the [35S] cysteine (1538 dpm) incorporation at indicated times.  C.  Aliquots 
of 5 µL were removed at indicated times and incubated for 30 minutes with 24 µL CAM 
[5].  The aliquots were precipitated with cold 10% trichloroacetic acid and collected on 
glass fiber filter by vacuum filtration.  The filters were dried and counted in a Multi-
Purpose Scintillation Counter (Beckman).  D.  Phosphorimage of [35S]cys-tRNAcys 
(300pmol and 1000 cpm/pmol) and ILCB·[35S]cys-tRNAcys; Lane 1, 300 pmol [35S]cys-
tRNAcys before reaction with biotin; Lane 2, 300 pmol [35S]cys-tRNAcys after reaction 
with biotin [N-iodoacetyl-N-biotinhexylenediamine]   (ILCB).  An aliquot of 2.5 µL 
were mixed with an equal amount of 10X urea-gel dye.  The samples were loaded on a 
6% urea acrylamide gel. 
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The aminoacylation of transcribed tRNAcys was monitored by the incorporation of 
[35S] cysteine.  The cys-tRNAcys synthesized was visualized by gel electrophoresis and 
staining (Figure 3.4A).   The reaction contained [35S] cysteine, and the amount of [35S] 
cysteine incorporated into the tRNAcys is shown in the autoradiogram (Figure 3.4B).   
The amount of [35S] cysteine incorporated in cys-tRNAcys increases with time as shown in 
Figure 3.4C.   The data shows that the tRNAcys is being aminoacylated over the course 
of the transcription reaction (see Figures 3.3C and 3.4C).  This suggests that the tRNAcys 
transcript is folded in the correct form and is immediately recognized by the synthetase in 
order to be aminoacylated.   Note that no denaturation or annealing was required for the 
tRNA to be properly folded and recognized by the synthetase. 
The assay for the quantification of the amount of [35S] cysteine incorporated is 
complicated by the behavior of cysteine with TCA precipitation.[29]  The free cysteine 
tends to precipitate and/or bind to nitrocellulose or glass fiber filters resulting in a very 
high background.   Modifications have been developed to circumvent this problem.   
One method developed by Hou et al [29] modifies the cysteine with CAM solution ( see 
materials and methods) prior to TCA precipitation.   Although this procedure eliminates 
the background issues, it is probably not 100% efficient in the detection of [35S] cysteine 
incorporated into protein.   A comparison between Figure 3.4A (actual stain) and Figure 
3.4B (autoradiogram) suggests the aminoacylation is reasonably efficient compared to the 
~10% aminoacylation obtained from the TCA assay.   In separate CTA experiments the 
efficiency was as high as 36% (data not shown).  This data is comparable with the data 
from personal communications with Dr. Y-M Hou where the efficiency of 
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aminoacylation is reported to be around 20-36%.   
These results suggest that the transcription reaction does not generate 100% full-
length tRNAcys or some portion is not folded correctly.   In addition, T7 polymerase is 
known to prematurely terminate transcription or to add untemplated nucleotides to the 3’ 
end of the transcript [125] which would adversely affect the aminoacylation of the 
transcribed tRNA by damaging the CCA end critical for aminoacylation.   Methods to 
improve fidelity of the 3’ end formation may increase the efficiency of aminoacylation.   
Purification of cysteinyl-tRNAcys.   The CTA reaction is a convenient method for 
preparation of aminoacylated tRNA.   However, the unincorporated nucleotides, 
cysteine and cysteinyl tRNA synthetase need to be removed prior to attachment of any 
reactive groups to the cys-tRNAcys.   It is particularly important to remove the 
unincorporated cysteine and cysteinyl-tRNA synthetase (CysRS), (contains five cysteine 
residues) to prevent labeling of the synthetase or free cysteine by the modifying agents 
(biotin or gold nanoparticles) which will reduce the yield of labeled tRNA. 
 The cysteinyl synthetase has a 6X histidine tag for purification, issued to remove 
the synthetase, and is removed batchwise from the CTA reaction by incubation with Ni-
resin.   The supernatant from the Ni resin is applied to Sephadex G25 spin-columns to 
remove unincorporated nucleotides and cysteine.   The flow through is collected, 
pooled and lyophilized. 
Modification of the cysteinyl-tRNA with biotin.  The next step is to demonstrate that 
the tRNA prepared using the CTA method may be further modified and functionalized in 
translation reactions.  The cys-tRNAcys was coupled to a biotinylated linker [N-
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iodoacetyl-N-biotinhexylenediamine] (ILCB) to make a biotin modified cys-tRNAcys 
(ILCB·[35S]cys-tRNAcys).  The iodoacetyl linkage was chosen for its reactivity to the SH 
group of cysteine, which yields a thioether that is stable in the reducing environment of 
the translation reaction.  Excess ILCB reagent was removed by Sephadex G25 spin-
columns and the flow through lyophilized. 
Degradation or loss of [35S] cysteine from the tRNA during the coupling process 
was not detected (compare lanes 1 and 2 in Figure 3.4D).  These results suggest that the 
modified cysteinyl-tRNAcys is stable over a reasonable time frame for purification.   
In Vitro Translation with [35S]cys-tRNAcys and ILCB·[35S]cys-tRNAcys.   To 
determine if [35S]cys-tRNAcys and ILCB·[35S]cys-tRNAcys were able to function in 
protein synthesis, a template for green fluorescent protein (GFP- containing 2 cysteine 
residues) was used in a commercial coupled transcription-translation reaction (see Figure 
3.5).  This system omits exogenous cysteine and should be dependent upon the addition 
of cysteine to the system in the form of cysteine, [35S]cys-tRNAcys or ILCB·[35S]cys-
tRNAcys.  Any incorporation of [35S] cysteine into GFP should have been provided by 
the [35S]cys-tRNAcys and ILCB·[35S]cys-tRNAcys.  However, it is expected that some 
free cysteine will arise from degradation of proteins in the S-30 extract.  The 
incorporation was monitored by SDS-PAGE and autoradiography.   As shown in Figure 
3.5A [35S] cysteine was incorporated into GFP from the [35S]cys-tRNAcys and depended 
upon the addition of the DNA template.   Similar experiments with the ILCB·[35S]cys-
tRNAcys are shown in Figure 3.5B.  [35S] cysteine was incorporated into GFP from the 
ILCP·[35S]cys-tRNAcys and depended upon the addition of DNA template.   Lastly, the 
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incorporation of ILCB·cysteine into GFP was monitored by detection of the biotin with 
streptavidin HRP (Figure 3.5B, second panel, lane 3).   
These results show that the tRNAs synthesized by the CTA method are functional 
in in vitro translation assays and as expected, biotinylation did not affect the ability of the 
tRNA to function. 
 Modification of the cysteinyl-tRNAcys with gold nanoparticles.   
The tRNA synthesized using the CTA method was functional in a translation 
mixture and could be modified with ICLB (biotin) that also functions in in vitro 
translation.   The next step was to modify the cysteinyl-tRNAcys produced in CTA with 








Figure 3.5.  In vitro translation using tRNAs synthesized by CTA. 
 A.  Lane 1, translation mixture containing [35S]cys-tRNAcys minus GFP plasmid 
template; Lane 2, translation mixture containing [35S]cys-tRNAcys containing GFP 
plasmid template (4 µg); [35S]cysteine incorporation into GFP was visualized with a 
phosphorimager.   B.  In both panels: Lane 1, translation mixture containing [35S]cys-
tRNAcys and GFP plasmid template (4 µg); Lane 2, translation mixture containing 
ILCB·[35S]cys-tRNAcys minus GFP plasmid template; Lane 3, translation mixture 
containing ILCB·[35S]cys-tRNAcys and GFP plasmid template (4 µg).  The 
phosphorimager shows the [35S] cysteine incorporated into GFP.  The biotin detection 
assay shows incorporation of ILCB·[35S]cysteine into GFP.     
 




Figure 3.6.   Scheme for purifying the cys-tRNAcys. 
 
 
The ideal nanoparticle for attachment to the cysteinyl-tRNAcys must have two key 
features.  1) It is very important to have just one possible reactive site on the surface of 
nanoparticle in order to limit the number of tRNA molecules reacting with the 
nanoparticle and  2) the nanoparticles must fit within the size parameters of what is 
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estimated the ribosome will tolerate (~2 nm).   A gold nanoparticle that has a single 
reactive monomaleimido group on the surface that will react with sulfhydryl groups is 
commercially available from Nanoprobes.  This type of gold monomaleimido 
nanoparticle, have been used extensively for labeling different biological substrates.[72, 
113, 123, 124]  These nanoparticles have a narrow size distribution, with an average 
diameter of 1.4 nm and are capped with triphenyl phosphines or halide ions and yet 
remain uncharged.  This nanoparticle has the appropriate properties to test the idea of 
ribosome assembly of a nanoparticle attached to an amino acid.   
The cys-tRNAcys prepared by CTA was modified with 1.4 nm gold 
monomaleimido nanoparticle.   To determine if the attachment of the gold nanoparticles 
to cysteinyl-tRNA was successful, several analytical methods were employed including 
electrophoresis, Laser Ablation-Inductively Coupled Plasma-Mass Spectrometry (LA-
ICP-MS) and High Angle Annular Dark Field (HAADF) techniques.   
 Electrophoresis of Au•cys-tRNAcys.   Surprisingly, electrophoresis results show no 
apparent change in mobility for the gold nanoparticle modified cys-tRNAcys (Au•cys-
tRNAcys) compared to unmodified cys-tRNAcys (see Figure 3.7A).   The gold 
nanoparticles used are uncharged (manufacturer specifications) and the average size of 
the gold nanoparticles (1.4 nm) is relatively small compared to the length of a tRNA 
(~7.5 nm, see inset in Figure 3.1).   The lack of charge and the small size of the gold 
nanoparticle compared to the negative charge of the tRNA could account for the lack of 
change in mobility.    
To test the charge of the gold nanoparticles, different amounts of un-reacted 
 68
nanoparticles (gold nanoparticles were dissolved in water and loading dye) were loaded 
on SDS-PAGE or denaturing urea/acrylamide gels and subjected to electrophoretic 
current.   No mobility of the nanoparticles was observed, regardless of the polarity of 
current applied (data not shown).    
Laser Ablation-Inductively Coupled Plasma-Mass Spectrometry (LA-ICP-MS).  
La-ICP-MS introduced in the late ’80, is one of the most commonly used techniques for 
sensitive multi- and/or single-element determination at trace levels.  Starting as a tool 
for determination of trace elements in geology, LA-ICP-MS (for solid samples) and ICP-
MS (for liquid samples) are now used as an analytical technique in biology, for example 
for medical sampling of trace elements in blood, urine and tissues.[126, 127]  LA-ICP-
MS is also used in material science, nuclear and radioactive waste monitoring.[126, 127]  
The laser (Light Amplification by Stimulated Emission of Radiation) used for ablation of 
the gold containing solid sample is a New wave Research LUV 213 which has a 
neodymium-doped yttrium aluminium garnet (Nd:YAG) laser source that produces a 200 
mJ beam of Infra Red (IR) laser light at 1064 nm.  The laser beam is polarized and then 
passes through a series of harmonic resonators resulting in a final beam of up to 5 mJ of 
213 nm ultraviolet (UV) light.  The spot size (5-400 µm range) used for all these 
experiment was 400 µm.  When the laser ablates the samples several process take place 
on the sample surface including melting, vaporization or ablation (which can be varied by 
adjusting the power density), followed by atomization and ionization, and the formation 
of a plasma near the sample surface which contains sample components.  The laser- 
generated plasma interacts with the sample and causes further ionization. 
 69
The helium or argon carrier gas transports the atoms, ions, molecules and particles 
to the ICP-MS, where they are ionized in the plasma. Once drawn inside the ICP-MS, the 
beam of ions is carried into a hexapole collision cell (containing hydrogen and helium 
gases).  Collisions with gas molecules in the hexapole thermalize the ion beam 
generating a beam with a smaller spread in kinetic energies.  The quadrupole mass filter 
rapidly switches setting to allow selected elements into the detector based on their mass 
to charge ratio and the detector records the number of ions entering per time period 
acquiring data in counts per second (CPS) of each element.[126-129]    
Laser Ablation ICP-MS of Au•cys-tRNAcys.   The Laser Ablation-Inductively 
Coupled Plasma-Mass Spectrometry (LA-ICP-MS) method may be used to detect gold 
and other elements.  This method is largely used for analysis of geological samples to 
detect various elements, but has been used in the analysis of selenium modified 
proteins.[130-136]  
The Au•cys-tRNAcys was separated on a urea gel, stained and dried between thin 
sheets of cellulose.   The region corresponding to the Au•cys-tRNAcys was cut out and 
placed on a glass slide for the LA-ICP-MS analysis.   Briefly, the laser beam moves in a 
straight line (transects) through the region of the gel containing the Au•cys-tRNAcys.   
The gel material containing the Au•cys-tRNAcys is vaporized and any Au released is 
detected and recorded by the instrument.  Using this method, the LA-ICP-MS analysis 
confirms that 197Au is present in the Au•cys-tRNAcys (see Figure 3.7B, panel a).   A 
series of control experiments shows that Au was not present in any area except that 
corresponding to the Au•cys-tRNAcys (see Figure 3.7B, p anels b-e).   
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Figure 3.7. Attachment of Monomaleimido gold nanoparticles (Au-MMA) to 
cysteinyl-tRNAcys.  Urea Gel Analysis of tRNA.   
Aliquots of 9 µg of cys-tRNAcys (cys) and Au•cys-tRNAcys (Au•cys) were mixed with an equal 
amount of 10X urea-gel dye.   The samples were separated on a 6% urea acrylamide gel.   The 
tRNA was visualized with 0.1% Stains-All (Sigma) and the gel dried.  B.  LA-ICP-MS 
detection of 197Au in tRNA.   The presence of 197Au in the modified tRNA and control samples 
was measured by laser ablation-ICP-MS (LA-ICP-MS) of a dried urea gel.    Each lane was cut 
in strips of 3.0 cm from the dried gel and mounted on a glass slide.   The glass slide and gel 
were placed in the ablation chamber and purged with He.   Gold was monitored by the ICP-MS 
as the laser traversed down the center of the lane.   Panel a, 9 µg of gold nanoparticle modified 
cysteinyl-tRNAcys (Au•cys-tRNA); Panel b, 9µg tRNAcys (not aminoacylated); Panel c, 9µg 
monomaleimido gold nanoparticles (Au-MMA); Panel d, 18 µg monomaleimido gold 
nanoparticles (Au-MMA) and 9 µg tRNAcys (not aminoacylated); Panel e, 9 cysteinyl-tRNAcys 
(cys-tRNA).    Panels b-e, are controls to demonstrate that the gold counts observed in panel a 
are from Au cys-tRNAcys (see broad peak at 10 min).  The very narrow areas of elevated counts 
(“spikes”) in the control traces (panels b-e) do not represent gold from a band in the gel but rather 
represent single particles entrained in the He carrier flow that were displaced from the wall of the 
ablation cell or tubing.   Similar spikes were seen in blanks of Helium passed through the 
ablation cell and tubing with the laser turned off.   In the tRNAcys (panel b) and cysteinyl-
tRNAcys (panel e) samples, no gold peaks were observed as expected.  The Au-MMA 
nanoparticles alone do not give any counts for 197Au in the area of the tRNA (panel c).  A 
reaction between the Au-MMA nanoparticles and the non-aminoacylated tRNAcys (panel d) also 
gave a flat background demonstrating that the Au-MMA cannot label the tRNA in absence of 
cysteine aminoacylation.  C.  High Angle Annular Dark Field image of Au•cys-tRNAcys.   3 
µL of Au cysRNAcys was placed on a copper grid coated with a thin, continuous carbon film.  D.  
Particle size distribution histogram.   The size distribution was calculated for 70 particles picked 
randomly from the HAADF image shown in Panel C.  (See appendix for larger image.) 
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These results demonstrate that the gold nanoparticles are chemically attached to 
the side chain of the cysteine, and non-specific binding between the gold nanoparticles 
and the tRNAcys did not occur.   
Transmission electron microscopy of Au•cys-tRNAcys.  To visualize the gold 
nanoparticle modified cys-tRNAcys, a transmission electron microscope (TEM) in 
scanning mode using the HAADF detector was employed.   The HAADF technique, 
also known as Z-contrast, is a straightforward approach to visualize nanoparticles in 
biological systems.[83, 137-140]  In this dark field technique, the images are formed 
using electrons scattered at high angles due to Rutherford-like scattering.   As a result, 
the image contrast depends on the atomic number (Z) of the visualized elements while the 
intensity varies as ~Z2.   In this case, the difference in atomic number between the gold 
nanoparticles and the protein (which is mainly composed of carbon), is high enough to 
produce an excellent contrast.[83] Based on the HAADF images, the particles were 
shown to have a narrow size distribution (see Figure 3.7C) and from the profile data they 
were spherical (not shown).   The size distribution was between 1.2 nm and 2.1 nm 
(standard deviation 0.2 nm) for the 70 particles randomly picked (see Figure 3.7D).  
From all the data collected one can conclude, that the gold nanoparticle was successfully 
attached to SH-group of cysteinyl-tRNA and inorganic nanomaterial modified aminoacyl-
tRNA (InAA-tRNA) was synthesized.    
Optimization of In vitro translation using Au•cys-tRNAcys.  The ability of the 
Au•cys-tRNAcys to be used in polypeptide synthesis was measured using an E. coli S30 
coupled transcription-translation system (Promega) with a template for green fluorescent 
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protein (GFP).    
 Previous experiments with the lysine system indicated that E. coli S30 translation 
system was not inhibited by gold nanoparticles.   However, the presence of 
dithiothreitol (DTT) in the translation mixture is a problem for the stability of the gold 
nanoparticles.  The DTT exchanges the tri-(aryl) phosphine capping agent present on the 
surface of the gold nanoparticles.  Thus, the gold is cleaved off and the tRNAs remain 
unmodified in the presence of DTT/BME.  The DTT is required to be present in the in 
vitro translation reactions, because it keeps the proteins from the S30 mixture active by 
preventing oxidation and/or the formation of disulphide bonds.  It was necessary to 
develop a method to scavenge the excess DTT which was detrimental to the gold 
modified cys-tRNAcys.   These steps were generally omitted to prevent any untoward 
damage to the gold nanoparticles.  Comparison of the LA-ICP-MS of lanes 2 and 3, in 
Figure 3.8C shows that DTT and heating are detrimental to the gold nanoparticle.   
 One solution tried, was to incubate the S-30 translation mixture containing 1 mM 
DTT with an excess of hydrolyzed gold nanoparticles.  The gold nanoparticles were 
kept in water for one week, the manufacturer specification indicate that the maleimide 
groups are hydrolyzed in few hours aqueous solution.  The coupled transcription-
translation reactions included an incubation of reaction mixture with the hydrolyzed gold 
nanoparticles for 15 minutes before the template was added to start the coupled 
transcription-translation reaction.  The reactions were analyzed by SDS-PAGE gels and 
LA-ICP-MS.  The LA-ICP-MS on dried 10-20% Tri-Glycine SDS-PAGE gels were 
inconclusive.   The presence of a shoulder of 197Au in the area of GFP suggested that 
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the gold modified GFP was synthesized but the signal was sufficiently low to be 
inconclusive.   
 The gold detection was hindered by the excessive amount of organic matter 
ablated and carried to the plasma.  The acrylamide gels containing the gold modified 
GFP was dried between layers of cellophane.  To reduce the amount of organic material, 
the proteins in the gel were transferred electrophoretically to a PVDF (polyvinylidene 
fluoride) membrane to improve 197Au detection (see Figure 3.8).  PVDF is a thin 
material that when ablated by the laser creates less organic matter to be burned in the 








 Figure 3.8.  In vitro translation using gold nanoparticle modified cys-tRNAcys 
(Au cys-tRNAcys) and an excess of hydrolyzed Au nanoparticles.   
A.  Detection of green fluorescent protein (GFP) in an E. coli coupled transcription-translation 
system (Promega) using a plasmid template encoding the gene for GFP.  The GFP template used 
contained a strep tag at the C-terminus which is detected by streptavidin -HRP.  TMB 
colorimetric substrate was used to visualize the GFP.  Lane 1, 7.5 µL of the translation mixture 
containing Au•cys-tRNAcys minus template; Lane 2, 7.5 µL of the translation mixture containing 
Au•cys-tRNAcys plus template (4 µg); Lane 3, 7.5 µL of the translation mixture containing 
Au•cys-tRNAcys plus template (4 µg), but no DTT was added to the loading buffer and the sample 
was not heated prior to loading on the gel; Lane 4, 7.5 µL of the translation mixture containing 
ILCB-cys-tRNAcys and Au•cys-tRNAcys plus template (4 µg); Lane 5, 7.5 µL of the translation 
mixture containing ILCB-cys-tRNAcys and Au•cys-tRNAcys plus template (4 µg), but no DTT was 
added to the loading buffer and the sample was not heated previously to be loaded on the gel.  
The samples were separated on a Novex 10-20% Tris–Glycine gel (Invitrogen) and transferred to 
a PVDF membrane.  B.  Detection of incorporation of 197Au into protein.  LA-ICP-MS was 
used to detect Au in the region of the PVDF membrane where GFP was detected (Lanes 3 and 5).   
Lanes 3 and 5 from the membrane shown in panel A were cut in strips (4 cm long and 0.9 cm 
width) and mounted on a glass slide.  The glass slide and gel were placed in the ablation 
chamber and purged with He.  Gold was monitored by the ICP-MS as the laser traversed down 
the center of the lane.  Lane 3 shows significant gold counts in the region where the GFP was 
detected meanwhile in Lane 5 shows less detection of Au in the same region.  C.  Detection of 
incorporation of 197Au into protein.  LA-ICP-MS was used to detect Au in the region of the 
PVDF membrane where GFP was detected (Lanes 1, 2, 3 and 5).  Lanes from the membrane 
shown in panel A were cut in strips (4 cm long and 0.9 cm width) and mounted on a glass slide.  
Lanes 1 and 2 shows significant less gold counts in the region where the GFP compared to Lane 3 
or 5. (See appendix for larger image.) 
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The in vitro translation experiment shown in Fig.  2.16 was carried out with 
excess hydrolyzed gold particles to scavenge up any excess DTT and prevent degradation 
of the Au•cys-tRNAcys.   The reactions were separated by gel electrophoresis and 
transferred to PVDF membrane for LA-ICP-MS analysis.  The LA-ICP-MS data clearly 
shows that Au•cysteine residues were incorporated into the GFP protein (see Figure 
3.8B).   The laser was traversed down the center of the lanes (3 or 5) generating a 197Au 
peak only in the region where GFP (~30 kDA) would migrate.    
  An “isotope dilution” effect is seen in the difference in the amount of 
Au•cysteine detected in lanes 3 and lane 5.   For lane 3, the only source for cysteine in 
the translation mixture is Au•cys-tRNAcys (3 nmols) whereas, in lane 5 equal amounts of 
Au•Cys-tRNAcys (1.5 nmols) and ILCB-cys-tRNAcys (1.5 nmols) were added.   The 
amount of Au•cysteine residues incorporated into GFP was reduced considerably if non-
gold modified tRNA is included in the translation mixture.   This experiment showed 
that an excess of gold particles could protect from degradation of DTT in the reaction 
mixture and that using PVDF for LA-ICP-MS analysis of the proteins vastly improved 
the detection of gold. 
Further refinement of the in vitro translation was necessary to insure that the gold 
modified cysteine residues visualized in the LA-ICP-MS were present due to the fact the 
Au•cys-tRNAcys was incorporated through the ribosome and not because the gold was 
attached post-translationally.  The excess hydrolyzed gold nanoparticles could have 
been a source of post-translational labeling; however, this possibility is very unlikely 
since gold was only detected in the region of the GFP.  The position of the GFP was 
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estimated from knowledge of the length and width of the PVDF membrane strips relative 
to the position of GFP on the PVDF based on visualization of the 14C-leucine 
incorporated.  Using the scanning rate of the laser the position of the 197Au-GFP peak 
was predicted.  The PVDF strips (40 mm long and 9 mm width) were scanned by the 
laser at approximately 4.8 mm/min.  The GFP is present approximately 25mm from the 
top of the strip which correlates to the 5 minute mark in the scan.  From Figure 3.8B, we 
can conclude that the 197Au peak appears in the region where the GFP is present (~5.25 
min). 
 Had post-translational labeling by the excess gold taken place, the gold would 
have been present throughout the gel since the translation mixture is an extract of E. coli 
proteins.   The concentration of the gold at the point in the gel where GFP should 
migrate strongly suggests the gold was incorporated by the ribosome.   The only other 
197Au peak present in the LA-ICP-MS spectrum was from the traces of cysteinyl–tRNA 
synthetase, which was not completely removed from the system using a Ni-NTA affinity 
matrix (see Figure 3.8).  The CysRS has five cysteine residues that are labeled with gold 
nanoparticles if no completely removed from the CTA reaction (Figure 3.8).    
To improve the efficiency of incorporation of Au•cys and to remove the need for 
hydrolyzed gold nanoparticles to scavenge excess DTT (1 mM), a large excess of 
Au•cys-tRNAcys (4-8 nM) was added to the reaction mixture.  Even if some of the 
Au•cys-tRNAcys was degraded by the excess DTT, a sufficient molar excess of the 
Au•cys-tRNAcys was still present for translation   
 These reactions were analyzed by SDS-PAGE and transferred to a PVDF 
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membrane for LA-ICP-MS analysis[135] (see Figure 3.9A).   The LA-ICP-MS data 
shows that Au•cysteine residues were incorporated into the protein, producing a peak in 
the region where GFP migrates (see Figure 3.9B, lane 4, ~3 minutes).  The control 
reaction contained Au•cys-tRNAcys and omitted plasmid template.  The absence of the 
gold peak (see Figure 3.9B, lane 3) in the control reaction demonstrates that the template 
is required for the assembly of Au•cys into the protein and cannot be added post-
translationally, otherwise gold would be detected throughout the gel attached to other 













Figure 3.9.  In vitro translation using gold nanoparticle modified cys-tRNAcys 
(Au cys-tRNAcys).    
A.  Incorporation of [14C]-leucine into green fluorescent protein (GFP) in an E. coli 
coupled transcription-translation system (Promega) using a plasmid template encoding 
the gene for GFP.   Lane 1, 7.5 µL of the translation mixture containing cys-tRNAcys 
(cys) minus template; Lane 2, 7.5 µL of the translation mixture containing cys-tRNAcys 
(cys) plus template (4 µg); Lane 3, 7.5 µL of the translation mixture containing Au•cys-
tRNAcys minus template; Lane 4, 7.5 µL of the translation mixture containing Au•cys-
tRNAcys plus template (4 µg).   The samples were separated on a Novex 10-20% Tris–
Glycine gel (Invitrogen) and transferred to a PVDF membrane.[  14C]-leucine 
incorporation into GFP was visualized by a phosphorimager.  The incorporation of 
[14C]-leucine into trichloroacetic acid precipitable material was used to estimate the 
amount of protein synthesized (~78 pmol/µL).  B.  Detection of incorporation of 197Au 
into protein.   LA-ICP-MS was used to detect Au in the region of the PVDF membrane 
where [14C]-labeled GFP was detected (Lane 4).   Lanes 3 and 4 from the membrane 
shown in panel A were cut into strips (4.3 cm long and 1.2 cm width) and mounted on a 
glass slide.   The glass slide and gel were placed in the ablation chamber and purged 
with He.   Goldwas monitored by the ICP-MS as the laser traversed down the center of 
the lane.Lane 4 shows significant gold counts in the region where the [14C]-labeled GFP 
was detected.   Lane 3 shows little detection of Au in the same region.   
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These data strongly suggest that the Au•cys-tRNAcys must enter and be used by 
the ribosome to assemble the polypeptide.    
Fluorescence Analysis of Au•GFP.   The presence of functional GFP was detected by 
fluorescence spectroscopy.  As shown in Figure 3.10 emission spectra depend on the 
addition of the GFP encoding template (see spectra 1 and 3) and cysteine (see spectra 1 
and 2).  Comparing the spectra 1 and 2, free cysteine is clearly present at some level in 
the S30 translation mixture which is incorporated into the GFP.  The free cysteine 
present in the system is generated from protein degradation in the S-30 extract.   
However, these results suggest that the amount of GFP obtained increased in the presence 
of the Au•cys-tRNAcys and therefore at least one of the cysteine residues in the GFP most 
likely contains a gold nanoparticle.   Improving the dependence of the translation 
system on exogenous cysteine would insure complete incorporation of the Au•cysteine at 
all the cysteine sites. 
At this point, no definitive statement can be made about the fluorescence of Au-
GFP.  The problem is the presence of a mixed population of GFP (unlabeled from the 
free cysteine) and gold modified GFP in the final translation mixture.  The only way to 
know if the Au-GFP is fluorescent is to incorporate the gold modified cysteine residue 
using a suppressor tRNA as the only source of gold. 
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Figure 3.10.  GFP emission spectra.  Fluorescent data were collected for 50 µL 
aliquots of: (1) the translation mixture containing Au•cys-tRNAcys plus template (4 µg); 
(2) the translation mixture containing the GFP encoding template but no cysteine was 
added to the reaction mixture; (3) the translation mixture containing Au•cys-tRNAcys 
minus template.   
 
Transmission Electron Microscopy of Au-GFP.   The High Angle Annular Dark 
Field (HAADF) technique was used to visualize the gold nanoparticles and determine if 
they were in the same region as the protein.   To obtain better results with the TEM, it 
was necessary to remove excess organic material (i.e, protein from the S30 extract).   
The GFP template used encodes a Strep-tag (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) on the 
C-terminus that binds biotin.   The Strep-tag provided a method to affinity purify the 
Au•GFP using Strep-Tactin beads (IBA).    
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Translation reactions containing Au•cys-tRNAcys and [14C]-leucine.   The [14C]-
leucine was used to monitor translation and the affinity purification process.   The 
protein eluted from the Strep-Tactin beads (see protocol in Materials and Methods) was 
analyzed by SDS PAGE (see Figure 3.11).  As shown in Figure 3.11B, [14C] leucine was 
incorporated into GFP and depended upon the addition of the GFP encoding template.   
The [14C] leucine incorporation also shows that the Step-Tactin bead can be used 
successfully to purify the gold modified GFP but some degradation was detected in the 
elution fraction (see Figure 3.11B lane 8).   
The HAADF image and Energy Dispersive Spectroscopy (EDS) analysis showed 
that gold nanoparticles were present in the same region as protein aggregates (see Figure 
3.9A).  A processed HAADF image, masking the noise caused by the organic 










Figure 3.11.  In vitro translation using gold nanoparticle modified cys-tRNAcys 
(Au cys-tRNAcys) which was affinity purified Step-Tactin beads.    
A.   The Coomassie stain of E. coli S30 coupled transcription-translation system 
(Promega) using a plasmid template encoding the gene for GFP.  Lane 1, 7.5 µL of the 
translation mixture containing cys-tRNAcys (cys) minus template; Lane 2, 7.5 µL of the 
translation mixture containing cys-tRNAcys (cys) plus template (4 µg); Lane 3, 7.5 µL of 
the translation mixture containing Au•cys-tRNAcys minus template-supernatant ; Lane 4, 
7.5 µL of the translation mixture containing Au•cys-tRNAcys minus template-wash ; 
Lane 5, 7.5 µL of the translation mixture containing Au•cys-tRNAcys minus template-
elution; Lane 6, 7.5 µL of the translation mixture containing Au•cys-tRNAcys plus 
template (4 µg)-supernatant; Lane 7, 7.5 µL of the translation mixture containing 
Au•cys-tRNAcys plus template (4 µg)-wash; Lane 8, 7.5 µL of the translation mixture 
containing Au•cys-tRNAcys plus template (4 µg)-elution .   B.  Incorporation of [14C]-
leucine into green fluorescent protein (GFP) for the gel from panel A.[  14C]-leucine 
incorporation into GFP was visualized by a phosphorimager.   
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Figure 3.12.  Visualization of Au-labeled protein synthesized by in vitro translation.    
The GFP template used contained a strep tag at the C-terminus.   The strep tag was used 
to affinity purify (Strep-tactin, IBA) the in vitro translated Au-labeled GFP from the E. 
coli extract.   The affinity purified protein (5 µL) was placed on a copper grid coated 
with a continuous carbon film. A.  HAADF image of Au GFP. B.  HAADF image from 
panel A was processed by masking the noise produced by the organic background in the 
Fourier Transform of the image in Panel A. C.  Particle size distribution histogram for 
Au•GFP in panel A.  The size distribution was calculated for 70 particles picked 
randomly from the HAADF image. D.  Energy Dispersive Spectroscopy (EDS) mapping 
for carbon.  E.  EDS mapping for Au.   F.  EDS mapping for S. 
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Figure 3.13.  Visualization of Au-labeled protein synthesized by in vitro translation.   
 The same affinity purified sample from Figure 3.9 but placed on a grid after 2 months of 
storage at -800C.   The affinity purified protein (5 µL) was placed on a copper grid 
coated with a continuous carbon film. A.  HAADF image of Au GFP. B.  Particle size 
distribution histogram for Au•GFP in panel A.  The size distribution was calculated for 
70 particles picked randomly from the HAADF imagE. c .  HAADF image from panel A 
at higher magnification. D.  Energy Dispersive Spectroscopy (EDS) mapping for 
carbon.  E.  EDS mapping for Au.  F.  EDS mapping for S. 
From the size distribution histogram, one can conclude that particles with diameters 
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within the range 1.2 -1.8 nm (standard deviation 0.2 nm), were incorporated into the 
polypeptide (see Figure 3.12. panel C).  If the size distribution histograms from Figure 
3.7D and Figure 3.12C are compared, it appears that the ribosome acts as a size exclusion 
machine, only particles less than 1.8 nm are present in the protein in contrast to the size 
range seen in the tRNA sample (see Figure 3.7).   
Overlaying of the carbon (Figure 3.12D and 3.13D), gold (Figure 3.12E and 
3.13E) and sulfur (Figure 3.12F and 3.13F) signals strongly suggests that the gold 
nanoparticles were present in the same region as the protein, entirely consistent with the 
gold nanoparticles being associated with the cysteine residues on the protein.  The 
HAADF image (see Figure 3.13) suggests that the gold modified protein is stable in 
elution buffer (100 mM Tris-HCl, 150 mM NaCl, 1mM EDTA, 2.5 mM desthiobiotin, 
pH 8) in time at -800C.   These results (LA-ICP-MS and HAADF analyses) confirm that 
the gold nanoparticles attached to cys-tRNAcys were incorporated into the protein by the 
ribosome and the intact gold nanoparticles were subsequently observed with GFP after 










The coupled transcription-aminoacylation (CTA) method was developed as a 
single step reaction, in which the tRNA is transcribed and aminoacylated in the same in 
vitro reaction mixture.  This method is efficient and eliminates the need to purify the 
tRNA prior to aminoacylation.   The ability of the tRNA to be aminoacylated by the 
synthetase suggest it must be correctly folded as it is transcribed to be recognized.   
Furthermore, the cys-tRNAcys may be modified with easily detectable functional groups 
(e.g., biotin) and still remain functional.  Both [35S]cys-tRNAcys and ILCB-·[35S]cys-
tRNAcys were successfully used to synthesize green fluorescent protein (GFP) in a 
coupled transcription-translation reaction (see Figure 3.5).  No phenol extraction, 
ethanol precipitation, or reannealing steps were performed on the tRNA, allowing for an 
efficient “single pot” synthesis of aminoacylated tRNA. 
Taking a step further, the E. coli cysteinyl-tRNAcys prepared using the CTA 
method was modified with an inorganic nanomaterial to form a new class of unnatural 
cysteinyl-tRNAcys.  The inorganic nanomaterial used was monomaleimido nanogold 
which has a single maleimido group on the surface and is very reactive towards the 
sulfhydryl group present on the side chain of cysteine.  This new class of gold 
nanoparticle modified cysteinyl-tRNAcys was used successfully in a coupled 
transcription-translation reaction to synthesize gold modified green fluorescent proteins.  
To prove that the Au-cysteine residues were incorporated into proteins electrophoresis, 




CONCLUSION AND FUTURE WORK 
 4.1. CONCLUSIONS: 
 
To address the question of whether nanoparticles attached to amino acids would 
be assembled by ribosomes into polypeptides, several experimental difficulties had to be 
overcome. 
Can large quantities of aminoacyl-tRNA modified by inorganic 
nanomaterials be prepared? 
One unexpected result of this work was the development of the coupled 
transcription-aminoacylation (CTA) method.[118]  This method is a single step reaction, 
in which the tRNA is transcribed and aminoacylated in the same in vitro reaction mixture.  
This method is efficient and eliminates the need to purify the tRNA prior to 
aminoacylation.  This method worked with both the lysine and cysteine systems.   
Recently CTA has been applied to Tyr-tRNAtyr from Methanococcus jannaschii and the 
Trp-tRNAtrp from Bacillus stearothermophilus (Randy Hughes, personal 
communication).   An interesting conclusion that may be drawn from the coupled 
system is that tRNA transcribed in vitro is folded correctly following transcription and 
does not require denaturation or reannealing prior to aminoacylation.  This new method 
of preparation of aminoacyl-tRNA was published in Analytical Biochemistry.[118] 
What is the best amino acid/synthetase pair to use?  The lysyl-tRNA was 
initially chosen for its reactive epsilon amino group; however, problems with the activity 
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of the lysyl synthetase, the requirement for post-transcriptional modification of the tRNA 
for maximal activity, and the need for more detection of the amino acid required another 
amino acid system.  The cysteinyl-tRNA system had the advantages of a robust 
synthetase, the tRNA did not require post-transcription modification and [35S]-cysteine is 
easily detected.  Further the reactive thiol group of cysteine may be modified with easily 
detectable functional groups (e.g., biotin) and still remain functional.   This system 
proved to be a robust method for the preparation of large amounts of cysteinyl-tRNAcys 
that was modified with a biotin group (ILCB).   Both [35S]cys-tRNAcys and ILCB-
·[35S]cys-tRNAcys were successfully used to synthesize green fluorescent protein (GFP) in 
a coupled transcription-translation reaction (see Figure 3.5).   
Can the aminoacylated tRNA be modified with a nanoparticle?  The E. coli 
cysteinyl-tRNAcys prepared using the CTA method was modified with an inorganic 
nanomaterial to form a new class of unnatural cysteinyl-tRNAcys.  The monomaleimido 
nanogold (~1.4 nm) has a single maleimido group on the surface and is very reactive 
towards the sulfhydryl group of cysteine.  This new class of inorganically modified 
Au•cys-tRNAcys is the first functional nanoparticle modified tRNA reported.   
Can the Au modification be monitored?  It was necessary to utilize new methods to 
detect the presence of the Au-nanoparticle on tRNA and incorporated into protein.   A 
method for detection of metals in geological samples, laser ablation inductively coupled 
plasma mass spectrometry (LA-ICP-MS) was utilized to detect the presence of gold in 
tRNA and protein.   The LA-ICP-MS method was very successful in proving the 
presence of gold in the modified tRNA and in in vitro translated protein.    HAADF 
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was also utilized to visualize the gold particles in tRNA and protein samples and confirm 
their size distribution. 
Can the ribosome use an inorganic modified aminoacyl-tRNA? The Au•cys-tRNAcys 
was used in a coupled transcription-translation reaction to synthesize green fluorescent 
protein.   Incorporation of the gold nanoparticle into protein was demonstrated using 
LA-ICP-MS and HAADF.   The inorganic nanoparticles (1.4 nm) do not appear to 
block the protein exit tunnel (~ 1.5 nm).   A comparison between the nanoparticles size 
distribution histograms for the tRNA (see Figure 3.7D) and synthesized protein (Figure 
3.12B) suggests that the ribosome appears to size select the nanoparticles.  The size 
distribution for gold nanoparticle modified cys-tRNAcys was 1.2 to 2.1 nm meanwhile the 
size distribution of gold nanoparticle incorporated into the proteins was 1.2 to 1.8 nm.  
No particle bigger then 2 nm was translated through the ribosome.   
This research proves that it is possible for the ribosome to be used as a 
nanomachine to assemble hybrid inorganic-polypeptide material.   This will open the 
way for the creation of unique inorganic-biological materials that will have new 








4.2. FUTURE DIRECTIONS: 
 
  The conclusion that the ribosome can translate inorganic modified aminoacyl-
tRNAs opens up several areas of interest and new directions for this research to explore.   
One area of prime interest is placing the nanoparticle in a precise location even if there 
are other cysteine residues encoded in a particular protein.   The technology for doing 
this with non-natural amino acids is already established using suppressor tRNAs.[60] 
Collaboration is underway with Randy Hughes in the Ellington laboratory for site-
specific incorporation of the nanoparticles to study potential applications, such as protein-
protein interactions, structure–function relations and protein folding.  Two categories of 
suppressor cysteinyl-tRNAcys, opal (UGA) and amber (UAG) have been prepared and 
modified with gold nanoparticles.   This novel gold modified suppressor cysteinyl-
tRNAcys will be used in coupled transcription-translation reactions to biosynthesize 
bacteriophage MS2 coat protein or GFP with a termination codon placed in a specific 
location.  If this method is successful, an in vitro continuous cell flow system to 
biosynthesize large quantities of a desired protein (milligrams amounts have been 
reported) and used study the behavior of these new inorganic/organic protein complexes 
Producing proteins with inorganic modified amino acids will have benefits in 
monitoring assembly of viral particles, e.g., a “gold studded” viral particle or a protein 
that has a single nanoparticles that may facilitate structural studies.   There applications 
are only limited by the success of optimization and preparation of large amounts of the 
suppressor tRNA.   
One area that needs to be optimized is the yield of aminoacylation.   The low 
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level of amino acylation (10-30%) is typical for in vitro transcribed tRNAs.   This is 
probably due to several factors, but most specifically to the incomplete formation of the 
tRNA-CCA 3’ end.   The –CCA 3’ end is crucial for amino acylation.   A method 
using primers with 2'-O methyl sugars to generate the transcription template by PCR[27, 
141] improves the amount of full length tRNA with the correct –CCA at the 3’ end of the 
transcript.   By improving the fidelity of the 3’ end, the amount of aminoacylated tRNA 
will be increased significantly.   Preliminary date suggests aminoacylation of up to 80-
90% may be possible by the CTA method with the 2'-O methyl sugars modified template.   
Improving the percentage of aminoacylated tRNA will improve the amount of 
synthesized protein.   
 
The possibility of the nanoparticle-amino acids systems to be used for translation 
of a polypeptide opens new opportunities in the elucidation of the tRNA dynamics when 
binding to ribosomes, peptide bond formation and protein folding.  The binding of gold 
nanoparticle to the aminoacyl-tRNA (in presence or absence of the linker) demonstrates 
the viability of interaction between two very different and complex systems, and opens 
new opportunities for the interactions of similar systems.  Besides the nanogold systems 
that are employed, other nanoparticle systems may be used when they become available 
with the appropriate single reactive groups and sizes.  Semiconductor-type systems like 
cadmium sulfide (CdS) and cadmium selenide (CdSe) could be used in addition to the 
other metal-type nanoparticles, such as cobalt. 
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If all the optimization problems can be overcome (generating large amounts of 
tRNA, finding less expensive, fluorescent nanoparticles, trouble shooting continuous 
flow protein synthesis to name a few).  This technology may be used to generate new 
types of inorganic/biological molecules and may also be used to study mechanistic 
aspects of protein synthesis such as using cryo-electron microscopy to localize the exit of 
the modified nascent peptide from the ribosome through the exit tunnel or the cleft.   At 
the very least this technology may be used to generate new types of inorganic/biological 
molecules with novel properties, such as conductive nanowire peptides that have 
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